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Abstract 
 
Plasmid DNA as a platform for the development of prophylactic and therapeutic 
vaccines against Clostridium difficile in aging models of disease 
 
Arjun Ramamurthi 
 
 
 
 
Clostridium difficile associated disease (CDAD) is a gastrointestinal disease whose symptoms 
range from mild diarrhea to pseudomembranous colitis and toxic megacolon. Statistically, it 
is among the most frequent hospital acquired infections in the United States, and is the 
leading cause of antibiotic-associated diarrhea in the developed world. Affecting roughly 
500,000 people in the U.S in the year 2011 alone, it was also identified as a top drug 
resistance concern in 2013. A significant fiscal burden, acute nosocomial infections alone 
cost $4.8 billion. Mortality in the elderly due to CDAD has skyrocketed in recent years, 
second only to septicemia and pneumonia, with the bulk of these cases being individuals >85 
years of age.  Advanced age, immunosuppression and antibiotic usage are the chief risk 
factors predisposing patients to CDAD.  
CDAD is mediated by two large exotoxins, tcdA and tcdB. These toxins bind to 
receptors on the surface of epithelial cells, and glycosylate Rho and Rac GTPases, causing 
actin cytoskeletal rearrangements and cell death. Protection from CDAD is mediated by 
antitoxin IgG antibodies, and there is a strong correlation between antitoxin IgG titers and 
disease outcomes. Immunosenescence, the age associated weakening of the immune 
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system, leads to a deficiency in these antibodies, causing the heightened susceptibility of 
aging individuals. There is a paucity of efficacious, protective vaccines against CDAD for the 
elderly, which is highly relevant given the high risk of recurrent disease in this demographic. 
While numerous platforms have been studied, very few data describe the potential of 
prophylactic and therapeutic DNA vaccination against CDAD in an aging mouse model of 
disease.  
Here, we test the immunogenicity of a DNA vaccine encoding the receptor binding domain 
(RBD) of the two exotoxins in an aging murine model. We hypothesized that aging mice that 
receive the DNA vaccine delivered by in vivo electroporation would produce a lower, but 
functional, antitoxin antibody response than young mice, and this response protects mice 
from a lethal infection. In this thesis, I tested highly optimized plasmids encoding the RBD 
from TcdA and TcdB and immunized aged C57BL/6 mice intramuscularly followed by in vivo 
electroporation. In the young adult mice, vaccination induced significant levels of anti-RBD 
antibodies within the serum that could neutralize toxins in an in vitro cytotoxicity assay. 
Aged animals had lower endpoint and anti-toxin neutralization titers compared to young 
mice post vaccination, but still elicited functional antibody. Both young and aged immunized 
mice were protected following orogastric challenge with strains of 105 cfu/ml C. difficile 
spores that were homologous to our vaccine antigens (VPI 10463; n=6/6). In addition, 
bacterial burden in immunized mice post challenge was analyzed, and revealed that aging 
mice had a higher bacteria load in their intestines when compared to young adults, but 
lower levels when compared to mice that received an empty plasmid immunization. These 
data demonstrate the protective immunogenicity and efficacy of a TcdA/B RBD-based DNA 
vaccine in young adult and aged mouse models of acute toxin-associated disease. 
We also tested an immediate  immune therapy platforms that could deliver anti-
toxin antibodies during severe acute infection for protection against CDAD in this thesis. We 
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posit that a new platform of DNA-encoded human monoclonal antibodies may be a viable 
option for an immediate treatment of CDAD upon diagnosis. We tested two DNA-encoded 
monoclonal antibodies (DMAbs) against the RBD of the toxins of C. difficile and evaluated 
their expression and functionality in vitro and in vivo. We show that the DMAbs are 
expressed by transfected cells, and specifically bind toxoids of the toxins. Additionally, we 
tested the temporal stability of the antibodies in vivo following a single vaccination in 
NOD/SCID Gamma mice and detected toxin specific antibody through day 21 post 
vaccination. Future studies will determine the ex vivo toxin neutralization by these 
antibodies, and the DMAbs will be tested for protection against lethal spore challenge in 
aged mice.   
In conclusion, the novel findings of this work are 1) the DNA vaccine encoding the 
RBD of C. difficile toxins A and B elicits a humoral response in aged mice, 2) antibodies 
elicited by this vaccine are functional, 3) Two immunizations protects young and aged mice 
from a lethal spore challenge, 4) infected old mice have a higher bacterial load than younger 
mice, but are still protected from morbidity and mortality, 5) DNA-encoded monoclonal 
antibodies are produced in vitro and are stable for at least 21 days in nude mice after a 
single immunization, and 6) these monoclonal antibodies are capable of binding toxoid 
antigen.  
These findings highlight the potential for in vivo electroporation delivered toxin-based DNA 
as a vaccine platform for prevention of CDAD, due to the ability to generate a strong, 
persistent humoral response that is protective in an aging mouse model of antibiotic 
associated diarrhea.  In addition, testing of DNA-encoded anti-toxin human monoclonal 
antibodies may be a viable option for an immediate treatment of CDAD upon diagnosis in 
high risk individuals, such as the elderly.  
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1.1 Microbiology  
Clostridium difficile (recently reclassified as Peptoclostridium difficile(1)) is a Gram 
positive, rod shaped bacterium. It was first isolated from the fecal contents of infants and 
neonates in a hospital environment(2). Like other members of the genus Clostridium, it is 
known to be ubiquitous in the environment, and commonly found in the environment, 
chiefly in soil. Although originally classified in the genus Clostridium, largely owing to its 
morphology, sporulation and inability to grow in the presence of oxygen, recent analysis of 
16s rRNA sequences and ribosomal protein genes have revealed that it is more accurately 
positioned in the Peptostreptococcacea family, altering its genus name to 
Peptoclostridium(1). This departure from classical methods of classification also explains its 
relative lack of homology with some members of the genus Clostridium.  
  An obligate anaerobe, C. difficile is a pathogen of the gastrointestinal tract, typically 
colonizing the duodenum, the upper third of the small intestine in humans. After initial 
colonization, which may or may not be symptomatic, disease manifests in varying degrees of 
severity, ranging from mild diarrheal disease to pseudomembranous colitis. A large array of 
risk factors and predispositions to C. difficile associated disease (CDAD) are complicit in the 
degree of symptomatic illness presented.  The association of C. difficile with 
pseudomembranous colitis was a key finding that led to its implication as a severe 
gastrointestinal pathogen(3). CDAD takes an unusual course, requiring an initial colonization 
event that is followed by ablation of intestinal microbiota to permit overgrowth and mediate 
its pathogenesis. This has led to the development of multiple approaches to control C. 
difficile infections (CDI), with efforts targeting both colonization and disease. A small fraction 
of the population  contains C. difficile as part of their normal microbiota, often being 
protected from CDAD. In addition to this, the phenomenon of colonization resistance, by 
which individuals resist colonization with C. difficile due to the unique makeup of  their 
microbiome, accounts for a population that is innately protected from CDI(4). However, at 
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least some portion of this population carries a non-toxigenic strain of the bacterium, which 
theoretically cannot produce the toxins that are the most potent mediators of CDAD. This 
colonization appears to protect these individuals from CDAD.    
 
1.1.1 Sporulation 
 
Sporulation is an important facet of the lifecycle of C. difficile that heightens its 
pathogenicity. The capacity to sporulate equips the bacterium with a strategy to survive the 
harsh external environment and the acidic conditions of the stomachC. difficile spores are 
found to be resistant to heat, oxygen and ethanol based sanitizers, as well as most 
commonly used disinfectants, which facilitate their spread and persistence in the 
environment(5). Under the right conditions, the spores germinate and thrive in the anoxic 
conditions of the small intestine, and the subsequent multiplication of the germinated 
vegetative cells leads to the development of CDAD.  Mechanistically, sporulation in C. 
difficile is like the well characterized system in Bacillus subtilis, owing to their phylogenetic 
proximity. Recent advancements in the genetic manipulation of C. difficile(6) have revealed a 
network of hundreds of genes that are directly involved in the sporulation process. While 
the general events in sporulation appear to follow the same template in both B. subtilis and 
C. difficile, there are some differences in the envelope of the spores, with C. difficile showing 
an altered structure. C. difficile also has a unique patterns of initiation and regulation of 
sporulation(7). C. difficile spores colonize a variety of mammals, including cows, pigs and 
horses(8). An early observation in the laboratory culturing of Clostridial spores indicated that 
the addition of taurocholate, a primary bile acid produced in the small intestine, and bile 
acid salts induced a marked increase in the germination and viability of spores isolated from 
fecal matter(9), while deoxycholate favored germination but suppressed vegetative cell 
growth(10). Analysis of these bile acids revealed a key role played by the microbiota in 
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facilitating germination of spores, with the bile acids that are secondary metabolites of 
intestinal commensals assisting in germination.  
1.1.2 Pathogenesis 
 
The pathogenesis of CDAD is a sequence of events that begins with colonization of 
the intestine. Colonization typically occurs through the ingestion of C. difficile spores. The 
spores then persist within the intestine until the environment favors their germination(10). 
Germination of the spores is driven by the ablation of the intestinal microbiome, usually by 
treatment with broad spectrum antibiotics. The germinated spores then produce two large 
exotoxins, tcdA and tcdB, which bind to receptors on the surface of intestinal epithelial 
cells(see Figure 1-1) (11, 12). The toxins glycosylate GTPases of the Rho and Rac superfamilies, 
causing rearrangements in the actin cytoskeleton and detachment of individual cells from 
the epithelium(13). The loosened epithelial layer then provides surfaces for adherence of the 
bacterium, through the action of another toxin, CDT (C. difficile transferase), also known as 
the binary toxin(14). The continued production of tcdA and tcdB exacerbates damage to the 
epithelium, ultimately resulting in the formation of pseudomembranes. Pseudomembranes 
are a marker of end stage disease, and are composed of necrotic intestinal epithelial tissue 
and leukocytes(3, 15). The accumulation of pseudomembranes results in the clinical condition 
called toxic egacolon, defined as an acute colonic distension greater than 6 cm in the 
transverse colon(16). Toxic megacolon, when caused by CDAD, is fatal in most cases.  
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Figure 1-1: TcdA, TcdB and CDT: Mode of entry and action A) The activity of TcdA and TcdB 
on cells: The CROP domain of TcdA binds to carbohydrates on the apical surface of the cell, 
while TcdB binds to Polio Virus Receptor Like3 (PVRL3). The toxins are internalized in an 
endosome, the low pH of which permits the autocatalytic processing and insertion of the 
toxin into the membrane. The toxin then glycosylates RHO and RAC family GTPases, which 
leads to breakdown of tight junction integrity. B) The Activity of CDT on Cells: Binary toxin 
binds to the lipolysis stimulated lipoprotein receptor (LSR) and is internalized in an 
endosome. CDTb forms a pore in the endosome, allowing the release of CDTa, which inhibits 
actin polymerization and permits increased adherence of the bacterium to cells.  Pamer et 
al, 2016(17). Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology (Abt, M. C., McKenney, P. T. & Pamer, E. G. Clostridium difficile colitis: 
pathogenesis and host defence. Nat. Publ. Gr. 14, 609–620 (2016)), copyright 2016 
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1.2 Toxins of C. difficile 
The toxins of C. difficile are part of the cluster of toxins referred to as Large 
Clostridial Toxins (LCT), which include botulinum toxin and tetanus toxin, both of which are 
highly lethal in miniscule doses. While less cytopathic than botulinum toxin, tcdA and tcdB 
are nevertheless potent enough to cause severe damage to the intestinal epithelium. These 
toxins exert their function by glycosylating G-protein coupled receptors of the Rho and Rac 
families(18). 
1.2.1 Toxin A 
Toxin A is a 308 kDa, single chain protein with four distinct functional 
domains(19)(Figure 1-2). These are the C-terminal binding domain (B in Figure 1-2), an 
autocatalytic processing domain (C in Figure 1-2), a translocation domain (D in Figure 1-2) 
and the enzymatic N-terminal glycosyltransferase domain(20)(A in Figure 1-2). The crystal 
structure of Tcd A was recently solved, permitting greater insights into its behavior and role 
in pathogenesis.(11) Each of these domains has been extensively studied(18, 20–22) to determine 
their exact role in cell death and infiltration, and to determine their potential as vaccine 
candidates.  
The binding domain contains a C-terminal combined repeated oligopeptides (CROP) 
domain, that contributes to cell surface receptor binding. The CROP region is capable of 
adopting a number of distinct conformations(11), enabling the whole toxin to assume a level 
of structural plasticity that might affect the immune response to it. A common hypothesis is 
that the receptor for TcdA may be a carbohydrate receptor that recognizes the heavily 
glycosylated nature of the toxin(23).  
The binding of the CROP domain to the as-of-yet unidentified receptor is followed by 
endocytosis(22). Within the endosome, pH changes lead to the insertion of the CROP domain 
into the membrane of the endosome, permitting insertion of the toxin into the cytosol of 
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the intoxicated cell. The cytosolic enzyme inositol hexakisphosphate(24) associates with the 
autocatalytic Cysteine Protease domain to cleave the toxin(21), releasing the 
Glucosyltransferase domain, which then proceeds to inactivate GTP-ases of the Rho and Rac 
families(20). This inactivation ultimately results in the repolymerization of the actin 
cytoskeleton, causing cell rounding and death, and disruption of epithelial junctions. 
1.2.2 Toxin B 
 
Toxin B is a 270 kDa single chain protein with identical biochemical organization to 
Toxin A (Figure 1-2).Toxin A and toxin B also share 47% amino acid homology and 68% 
similarity(20), and this similarity is a potential advantage in generating an immune response 
against the two toxins, with cross-reactivity being a probable event. Toxin B has not been 
crystallized , with most assumptions about its structure and function being largely derived 
from the better understood Toxin A(11). Toxin B enters cells and exert its function in largely 
the same manner as Toxin A(20), allowing therapeutic approaches to both toxins to mirror 
each other, simplifying vaccine design. It is important to note that Toxin B is an order of 
magnitude more potent and cytopathic than Toxin A, and possibly more involved in CDAD(25). 
The increased cytopathic effect is evidenced by both in vitro and in vivo assays measuring 
the viability of cells exposed to the toxin as a measure of cytopathic effect(26). Until recently, 
the cell surface receptor of both toxins was unknown, adding to the challenge of studying 
the behavior of these toxins in vitro and in vivo. There at least two different types of 
receptors that have been identified as possible methods of entry for Toxin B. These include 
the Polio Virus Like 3 (PVRL3)(27) and the frizzled receptor family(28). The identification of 
multiple receptors for Toxin B could provide some insight into its greater potency.   
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1.2.3 Binary Toxin (CDT) 
 
Binary toxin, also known as CDT, is a supplemental toxin that is present in some 
strains of C. difficile. It is markedly different from toxins A and B, in structure, biochemical 
organization and function. CDT is produced as two independently synthesized subunits, 
CDTa and CDTb, CDTa is the enzymatic component, and is 48 kDa (Figure 1-2 B). CDTb is the 
transport component, and is 74 kDa(29) (Figure 1-2 B). While the exact role played by CDT in 
the pathogenesis of C. difficile is unclear, it is known to enhance adhesion of the bacterium 
to the intestinal epithelium(14). It also exacerbates illness and cellular damage in late stage 
pseudomembranous colitis, which is the most severe manifestation of CDAD(30).  
CDTa is an ADP-ribosyltransferase(31), which causes cellular damage by forming 
microtubule protrusions and actin ribosylation, causing depolymerization of microtubules 
and disruption of cellular architecture. These protrusions enable enhanced adherence of the 
bacterium to the intestinal epithelium, heightening virulence. CDTb is responsible for 
binding of the toxin to cell surface receptors, allowing  entry of the toxin into the cell in a 
manner similar to tcdA and tcdB. The receptor involved in this process is the lipolysis-
stimulated lipoprotein receptor (LSR)(32). The binding of CDTb to  LSR is closely followed by 
endocytosis, resulting in the entry of the toxin into the cell within an endosomal vesicle. 
Cleavage of the enzymatic component of the toxin depends on acidification of the 
endosome, the low pH enabling CDTb to form pores in the endosomal membrane, releasing 
CDTa(13).  Owing to its relatively minor role in CDAD and absence in some strains, CDT is not 
commonly a vaccine target, but a study using it in conjunction with functionally weakened 
tcdA and B found that this formulation was protective against challenge with the NAP1 
strain(33).   
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A) 
 
B)  
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Figure 1-2: Biochemical organization of TcdA, TcdB and CDT A) Biochemical organization of 
TcdA and TcdB: There are 4 domains, A: Glycosyltransferase domain which exerts the 
function of the toxins, B: Receptor Binding domain C terminal domain that binds to cell 
surface receptors, C: Autocatalytic processing domain, involved in the cleavage of the toxin 
upon entry into the endosome and D: Translocation domain, which permits the insertion of 
the toxin into the endosomal membrane. B) Biochemical organization of Binary Toxin, 
produced as two individual components. CDTa- ADP Ribosyltransferase domain, containing 
an N-terminal signal peptide, which is cleaved to release the 48 kDa N and C terminal 
domains that exert the functions. CDTb contains an activation domain that must be cleaved 
to yield the functional CDTb component.  
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1.3 Strains and Toxinotypes 
 
A toxinotype of C. difficile is defined as a collection of strains with identical 
mutations in the Pathogenicity Locus( PaLoc) when compared to other strains(34).  A primary 
differentiation to be made in this regard is between toxigenic and non-toxigenic strains, 
based on their ability to produce toxins A and B. Further, two distinct types of variants have 
been identified, based on toxin-gene rearrangements and toxin-production, with altered 
gene expression patterns not necessarily leading to the expression of a single toxin at the 
exclusion of another(34).  
C. difficile, like all bacterial species, displays a large amount of intraspecies variability, with 
multiple strains identified. Different strains flourishing in diverse geographical locations. The 
strains are primarily differentiated by PCR ribotyping, pulse-field gel electrophoresis, 
restriction enzyme analysis and variable number tandem repeat analysis. Variations usually 
manifest in altered phenotypes, which include presence or absence of flagella, as well as 
altered levels of toxins A, B and CDT.  
Increased analysis and more efficient diagnosis of CDI has led to a number of 
noteworthy epidemiological events, chief among these being the increased diagnosis of the 
hypervirulent strain known as BI/NAP1/027(35). The discovery of this strain in 2005 was a key 
finding, with its subsequent isolation in nearly all areas of the world(36). A deletion in the 
tcdC repressor region (that transcriptionally inactivates the toxin locus), facilitates the 
production of increased quantities of tcd A and tcd B in this strain, contributing to its 
markedly increased virulence(37). This strain produces large quantities of an antigenically 
variable version of Toxin B(38), contributing to its increased pathogenesis. 
In addition to variability in strains, 24 toxinotypes have been identified, based on 
mutations and gene expression patterns in the toxin producing pathogenicity locus (PaLoc). 
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PCR-Ribotyping has been used to identify the toxinotypes of C. difficile (34), based on the 
sequence differences from the reference strain VPI10463 (assigned the toxinotype 0). 
Depending on the degree of mutations in the PaLoc, toxinotypes are referred to as major or 
minor.  
There are seven possible toxin-producing phenotypes of C. difficile, relative to the 
combination of tcdA, tcdB and CDT expressed by a strain. Toxinotype 0 displays the 
phenotype A+B+ CDT-, while the BI/NAP1/027 strain displays A+B+ CDT+, and is assigned the 
toxinotype IIIB(34). Both A-B+ and A+B- strains have been identified and isolated from clinical 
samples, implying that single toxin producing toxinotypes can cause CDAD. This diversity is a 
point to consider with respect to vaccine design. Based on the conservation of a chosen 
antigen across the toxinotypes of C. difficile, it might be necessary to develop consensus 
immunogens, to provide the maximum breadth of protection. 
 
1.4 Epidemiology 
 
C. difficile is a swiftly escalating problem in the developed world today, with a complex 
epidemiology. New infections are most commonly nosocomial (See Figure 1-3) or healthcare 
associated, but recent years have revealed an increase in the number of community onset 
infections as well. The advent of hypervirulent strains like the NAP1/027 has greatly 
increased the numbers of both cases and fatalities(39), underlining the need for new 
strategies to combat CDI, in terms of infection control as well as therapy. The number of 
cases of CDI has been steadily rising since it was identified as a cause of antibiotic-associated 
diarrhea, in 1978(40). A sharp increase in the number of hospital admissions owing to CDI and 
CDAD can be detected in epidemiological data from the early 21st century(39), a finding which 
correlates with the advent of hypervirulent strains(41). In addition, the emergence of MDR 
bacterial pathogens contributes to this upturn in cases of CDAD, as the usage of larger 
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quantities of antibiotics favors the environment that C. difficile spores thrive in(42).  A report 
from the CDC estimates that there were 493,000 cases of CDI in the year 2011, with 29,000 
deaths(43) in the United States alone. This number is expected to increase over the next 10 
years, with the number of cases approaching 1 million per annum. Critically, this study found 
that only 24% of all cases were hospital-acquired, indicating that the problem is no longer 
contained to healthcare facilities and employees(43). The economic burden of CDAD is also 
worth noting, as primary and acute infections are projected to cost the healthcare system 
$4.8 billion annually(44). 
1.4.1 Routes of Transmission and Colonization 
 
An unusual facet of CDI is the necessity for a colonization event, that precedes 
symptomatic disease. Colonization refers to the ingestion of C. difficile spores and the 
ablation of the intestinal microbiome, allowing the spores to germinate. In most cases. this 
colonization occurs in a healthcare environment, either at a hospital or at a long-term care 
facility. The initial exposure, reliant on the ingestion of spores, is often asymptomatic and 
seldom detectable. A review of clinical studies of CDAD estimated that 10% of patients were 
colonized with toxigenic C. difficile upon admission to a hospital in North America alone(45). 
These colonized individuals are more likely to develop disease. They are also asymptomatic 
carriers(46)(47), who shed spores and contribute to the spread of CDI in the community 
Nosocomial infections may also spread due to the persistence of C. difficile spores in the 
environment, and on hospital equipment(48, 49). Carriage of infections by healthcare workers 
and transmission outside healthcare environments has been proposed as a potential source 
of community onset infection, but there is insufficient data to back this claim. . The time 
between exposure to C. difficile and the development of CDI is estimated to be between 2 
and 3 days(47, 50, 51). 
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 1.4.2 Clinical Disease 
 
Clinical disease is defined as the presence of symptoms (usually diarrhea), along with 
the presence of toxigenic C. difficile or toxins in the stool, or endoscopic evidence of 
pseudomembranous colitis(52). It manifests in a variety of ways, ranging from asymptomatic 
carriage to fulminant disease(39). The most common presentation is severe diarrhea, which is 
watery and may contain mucus or stool, also emitting a foul odor. The frequency of diarrhea 
is a useful indicator of CDAD in the clinic. Late stage disease entails the development of 
pseudomembranous colitis (PMC)(3), which results in the fatal condition referred to as toxic 
megacolon(16).  PMC is detected by colonoscopy, and is associated with large quantities of 
tcdA, tcdB, CDT and localized cell death(15). Pseudomembranes are theorized to be biofilms 
of C. difficile(53), owing both to their microenvironment and their impenetrable nature, which 
greatly limits the efficacy of antibiotic treatment. Owing to the potency of the disease, and 
the fatality associated with toxic megacolon (an end stage manifestation of clinical disease), 
CDAD rarely progresses to the stage of septicemia, due to the fact that severe infections lead 
to mortality before the bacterium can enter the bloodstream. In addition, the aerobic nature 
of most tissues precludes them from being infected with obligate anaerobes like C. difficile.   
1.4.3 Risk Factors 
 
The bestl studied risk factors predisposing individuals and populations to CDI are 
advanced age and antibiotic usage. In the following section, I will summarize the literature 
that supports these host factors as increasing risk to CDI and CDAD.   
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1.4.3.1 Age 
 
Aged individuals remain the population at highest risk of recurrent CDI, with patients 
greater than 65 years of age being 20 times more likely to develop disease than younger 
individuals(39). Aged individuals who have frequent hospitalizations and/ or reside in long 
term care facilities are highly at risk of developing recurrent CDI. The immune deficits 
commonly associated with senescence are responsible for this heightened sensitivity, which 
is reflected in vaccine design, with clinical trials testing the Pfizer, Sanofi and Valneva 
vaccines only recruiting patients above the age of 65(54–56).  
The current understanding of the defects in aging immune systems indicate that the 
problem lies in the weakened humoral response, which is unable to produce high affinity 
antibodies to the toxins of C. difficile(57). This flaw is based off a reduced number of naïve B-
cells, as well as a reduced number of class-switched memory cells, which are predictors of an 
effective antibody response(58, 59).  In addition to this, T-cell help is inhibited by the presence 
of exhausted T-cells, which further attenuates the adaptive immune response(60). An 
evolving elucidation of the innate immune response indicates that there are defects in 
neutrophil functions(61) and the relative distribution of monocyte subsets, resulting in 
impaired phagocytosis(61, 62) crucial to the response against C. difficile that render these first 
line defenses ineffective against the disease(63),(64). The inability to produce high affinity 
antibodies post both vaccination and infection pose a challenge to all vaccine development, 
with at least one clinical trial (Sanofi Pasteur) failing due to less than 80% seroconversion 
post vaccination.  
1.4.3.2 Antibiotic Usage 
 
The next most commonly associated risk factor to CDI is the usage of broad 
spectrum antibiotics. Chronic infections and use of antibiotics are the next important risk 
factors, with a combination of these with advanced age proving to be a near certain cause of 
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recurrent CDAD(46). Broad spectrum antibiotics are implicated in heightening susceptibility to 
CDI, owing to the indiscriminate ablation of the healthy gut microbiome, especially depleting 
anaerobes. The consistent overuse of antibiotics, while causative of other problems 
including antibiotic resistance, permits an almost cyclic recurrence of C. difficile overgrowth 
and disease, given that there is no opportunity for the gut to return to its initial state and 
microbial composition(36, 39). This dysbiosis is also related to secondary infections that require 
a similarly altered intestinal milieu. 
1.4.3.3 Immune Suppression 
 
Immune suppression has emerged as a leading confounder of CDI, with the inability 
of the immune response to clear the initial infection allowing the unchecked growth of C. 
difficile, and the resulting disease(65),(66). Clinical studies in transplant recipients have 
revealed that heart, liver and other solid organ transplants are associated with CDAD, with a 
window of especially high susceptibility to the disease following the actual 
transplantation.(67, 68) Cancer patients, the next largest population of individuals on immune 
suppression, are at greater risk of developing CDAD than the average hospitalized individual. 
In addition to this, a strong correlation between chronic HIV infections and susceptibility to 
episodes of CDAD has been established in clinical studies(65).  Immunosuppressed patients 
are most likely to benefit from effective immunotherapy that can help them manage CDAD 
without the need for a strong self-generated immune response.   
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Figure 1-3: Increased occurrence of Nosocomial CDI:  The number of hospital acquired 
infections, arranged in order of the population demographics separated by age groups (lines 
labelled ≥85 years, 65-84 years, 45-64 years, 18-44 years and <18 years). The blue line 
indicates the overall occurrence of CDI. Reproduced with permission from Leffler et al, 
2015(41) 
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1.5 Immune Responses to C. difficile toxins 
 
The immune system offers three potential barriers to the toxins of C. difficile, all of 
which are crucial in controlling infection and disease(69). Barrier immunity provided by the 
architecture of the intestinal epithelium and the immune cells that are located within the 
tissue, offers the first line of defense.  Innate immunity mediated by neutrophils, 
macrophages and innate lymphoid cells(70), is the next arm of the protective response, 
essential in the earliest stages of the infection.  The adaptive immune response, that is 
primarily humoral, that relies on antibodies against the toxins(70), is the most important 
aspect of the host defense against C. difficile toxins, and takes the longest time to activate . 
The toxin virulence factors of C. difficile elicit a strong pro-inflammatory response(71), the 
extent of which defines if it is helpful or harmful. Overstimulation of the inflammatory 
response for extended periods of time is more deleterious than helpful to the overall 
clearance of the infection. The innate immune response is engaged after the disruption of 
the intestinal epithelium, and is mediated primarily by non-enzymatic activities of tcdA and 
tcdB(72).  The adaptive immune response targets the toxins, effectively preventing them from 
exerting their enzymatic functions . This is done by antibodies produced by antigen specific B 
cells, which bind to the toxins before they can engage their cellular receptors. In this way, 
antibodies prevent the initial binding of the toxins to the epithelial cells, maintaining the 
integrity of the barrier. Thus, the adaptive immune response has more of a role to play in 
controlling disease, but not prevention of infection, as discussed below, given the time taken 
for its activation and to exert an effect.  A strong, specific antibody response is capable of 
protection from recurrent disease, by binding secreted toxins and maintaining epithelial 
integrity.  
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1.5.1 Innate Immune Response 
 
The key players in the innate immune response are mucosal immune cells, which 
include macrophages, monocytes, mast cells, neutrophils and innate lymphoid cells (ILCs). 
Chronic immune activation is caused by the secretion of large quantities of the neutrophil 
chemoattractant IL-8,(73) the production of which is stimulated by tcdA in intestinal cells. This 
activation is NF-ĸB dependent. TcdB stimulates IL-8 production differently, reliant on a 
different receptor interaction(74). Temporally, IL-8 production preceded RHO-glycosylation, 
indicating that these activities are non-enzymatic.  
In addition, the interaction of tissue resident macrophages with the toxins results in 
the production of MIP-2α(75).MIP-2α  further stimulates neutrophil trafficking. The toxins are 
also implicated in oxidative damage to the intestinal tissue, modulated by the production of 
reactive oxygen species (ROS). The next large innate immune component to be activated by 
tcdA and tcdB is the inflammasome. Both toxins activate the inflammasome in identical 
fashion, leading to the release of large amounts of IL-1β and IL-18, both of which continue to 
promote the inflammatory environment(76). TLRs and NOD proteins are the most important 
PRRs that recognize PAMPs on C. difficile. NOD1 recognizes a unique signature on the cell 
wall of C. difficile(77), while TLR 4 and 5 recognize the cell surface protein and flagella 
respectively.  
As with most bacterial pathogens, the exact role of ILCs is yet to be clearly defined. 
However, preliminary studies into their role in controlling CDI have revealed that IFN-γ 
secreting type 1 ILCs have an important role to play in the process(78). This also provides a 
role for NK cells, which are not typically associated with the immune response to bacterial 
pathogens. In summary, the innate immune response is primarily mediated by macrophages, 
monocytes and neutrophils, which all create an inflammatory microenvironment. The 
efficient control of this inflammation leads to the timely phagocytosis and clearance of C. 
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difficile . In cases where inflammatory and innate control is lost, the unchecked 
inflammation causes extensive tissue damage and hastens the formation of 
pseudomembranes within the infected tissue.  
 
 1.5.2 Adaptive Immune Response 
 
The adaptive immune response to the toxins of C. difficile is primarily humoral(70), 
with antibodies that bind the toxins being the primary determinants of immunity. The two 
toxins, while similar in structure, are immunologically distinct(69). The antibodies raised 
against both these toxins are distinct from each other, and may not cross react, while 
performing the same function of neutralizing toxins before they enter cells. 
IgM responses are the first, low affinity responses to CDI, which are temporally associated 
with severe, acute infections(70). IgM is not thought to be effective in the control of CDI, but 
has been shown to have some degree of neutralizing capacity, which may supplement the 
activity of IgG and IgA.   
The primary isotype of antibody involved in immunity to C. difficile is IgG. 
Specifically, subclasses IgG2 and IgG3 have been associated with protection from recurrent 
CDAD(79). Clinically, serum IgG is a correlate of protective immunity from recurrent 
infection(80). IgG is also detected in the mucosal surfaces, where it can access the toxins 
released by the bacterium. Functionally, the IgG neutralizes the toxin by binding to the 
toxins, preventing their entry into the cells and thus preventing them from exerting their 
effects. Sufficient quantities of IgG have been associated with protection of the intestinal 
architecture and prevention of cell death(79). Toxin neutralization is the key determinant of 
immune protection from CDAD, and has been used as a method of in vitro validation of IgG 
functionality(81).   
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 Mucosal IgA is also important to the clearance of CDI. Dendritic cells (DCs) in the gut 
promote a TH2 response, leading to the production of IL-10 and a control of inflammation, as 
well as inducing B-cells to class switch to producing IgA. Numerous studies have associated 
IgA with functional blocking of toxins, and their correlation with protection from severe 
disease(69, 70, 82, 83). The levels of IgA were found to be higher in acute infections than in 
recurrences(43). It is important to note that the adaptive immune response is not involved in 
the clearance of acute infections, but is vital to prevention of recurrent CDI. This is mostly 
because of the time needed to raise an effective adaptive immune response. Studies 
investigating the role of T-cell help in the generation of both IgG and IgA have indicated that 
CD4+ T-cells are necessary to produce IgA, but systemic IgG levels are unaffected(84) in T-cell 
knockout mice, further highlighting the relative redundancy of the cell mediated response.  
In conclusion, neutralizing antibodies that can bind to the toxins are the critical 
determinants of the adaptive immune response to C. difficile toxins. While effective in 
controlling recurrence of infections, the adaptive immune response has no role to play in 
clearing acute infections. Systemic IgG and mucosal IgA are crucial in preventing intestinal 
cell necrosis and maintaining the architecture of the epithelium.    
 
1.6 The Aging Immune Response 
 
The etiology and epidemiology of CDI highlight the importance of the immune 
response in aging populations(39, 41, 43), and the differences and weaknesses that make these 
populations more susceptible to recurrent CDAD. The immune response in aging individuals 
is also crucial to vaccine development, with multiple vaccine trials against C. difficile antigens 
failing due to a lack of seroconversion in aging participants(85).  
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Immune senescence is a complex, nuanced phenomenon that evades rigid 
classification. Phenotypically, there are defects in one or more cell types, often distributed 
non-parametrically in analyzed cohorts. These defects are not isolated to any arm of the 
immune system, with both innate and adaptive defects being detected(64),(57, 86).  
The attenuated immune response is a heavy contributor to the prevalence of 
recurrent CDI in elderly individuals, being unable to clear infections that are antibiotic 
resistant(42, 87). In addition to this, the ablation of the microbiome with antibiotics further 
jeopardizes the individual’s immune response to mucosal pathogens, simultaneously 
heightening risk and weakening the response.  
Aging as a biological process is incompletely understood. However, it is known to 
have a weakening effect on the immune system in its entirety. Thus, it is uniformly difficult 
to augment all the individual arms of the immune system, using vaccines or immunotherapy. 
This offers the biggest challenge to the development of vaccines for the aging. 
A common pathological process in most aging related illnesses is ‘Inflammaging’, 
which is a low-level infiltration of aging tissue with innate immune cells, and elevated levels 
of inflammatory mediators like IL-6 and C- reactive protein (CRP)(86, 88). This reaction may be 
isolated to tissue microenvironments or may be systemic(63). The phenotype of the cell 
infiltrate in this process remains to be elucidated, but an educated guess would assume that 
at least some proportion of these cells are non-functional or have altered functionality.  
The implications of aging on the T-cell response have been studied in detail, 
especially in the light of HIV-1 infections, given the crucial role of T-cells in HIV. It is 
understood that the translocation of microbial products and the sustained activation of the 
immune response in these contexts lead to an accelerated aging process that leads to T-cell 
exhaustion, which decreases their effector functions(89).  
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In the context of CDI however, the aging B-cell response is of greater relevance,as 
the outcome of aging individuals with weaker antitoxin antibody responses is significantly 
worse than individuals with a strong response(90, 91) Since immunity to CDI is primarily 
humoral, the phenotype of aging antibody responses, and their quantitative and qualitative 
differences from the adult responses merit greater study. The number of circulating B-cells 
decreases with age, with a change in the relative frequencies of specific subsets of B-cells, 
reducing the number of naïve cells and increasing the number of terminally differentiated 
cells(57). These terminally differentiated cells may be exhausted, meaning they are senescent, 
producing pro-inflammatory cytokines upon activation(92). There is also a reduced number of 
plasma cells in the bone marrow of aging individuals, which automatically leads to a 
decrease in antibody levels. Class switching frequency decreases, and a significant part of 
the antibody response to primary infection in these populations is a low affinity IgM 
response(59). The germinal center reaction is also impaired by aging, given that TFH cells are 
less functional, and thus offer less efficient help to B-cells in the lymph node, with the 
resultant antibodies produced by this reaction significantly lower in effector functions and 
affinity(93). There is an increase in the number of TFR cells, which secrete IL-10 and are known 
to be potent suppressors of GC B-cells(93). 
1.7 Vaccines Against C. difficile 
 
There is no licensed vaccine to C. difficile currently available. However, there are 
several different vaccine candidates currently being evaluated, both at the preclinical and 
clinical testing stages(33, 94–98). The vaccine approach is largely split along two separate 
rationales, one focus on vaccines that target colonization and prevention of initial infection, 
and the other targeting prevention of disease and recurrence. The choice of antigens and 
the vaccine platform being used is largely dictated by these two central ideas. The field of 
vaccines targeting colonization is not the focus of this thesis, thus will not be expanded on in 
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this introduction. In addition, research to develop vaccines that target C. difficile 
colonization is slightly sparser than those targeting disease, and not as far in the pipeline for 
clinical development when compared to vaccines targeting toxin-mediated disease. The 
increasing number of asymptomatic carriers of C. difficile further limits the number of 
people a vaccine against colonization would benefit.  
In addition to these active immunization strategies, there is a growing shift towards 
passive immunotherapy as a potent tool, especially with respect to control of acute, 
symptomatic disease. Here, I will summarize active immunization strategies, in which 
multiple antigens have been targeted, with the most conserved antigens being flagella, cell 
surface proteins and the toxins, as well as passive immunotherapy strategies. Importantly, 
active immunization methods have thus far shown some success in initial trials, although 
they have obtained less satisfactory seroconversion in aging cohorts.   
 
1.7.1 Active Immunization Strategies 
 
The goal of any vaccine is the generation of a strong initial host response to the 
pathogen coupled with the development of a robust memory immune response. Active 
immunization strategies remain the most potent method of engendering a quality immune 
response that fulfils these goals. Active immunization regimens targeting both colonization 
and toxin-induced C.difficile associated disease are currently in clinical trials.  
 
1.7.1.1 Prevention of Colonization 
 
Logically, the transmission of C. difficile from patient to patient in any healthcare 
facility could be controlled by a vaccine that prevents colonization, or alternatively, a vaccine 
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that prevents transmission of spores and bacteria. There is also an effort directed at using 
non-toxigenic strains as a vaccine, given that individuals colonized with non-toxigenic strains 
display markedly milder disease symptoms.  
Colonization of the intestine is intrinsically dependent on the binding of the 
bacterium to the intestinal epithelium, and its adherence to epithelial cells is the limiting 
factor in this situation. Thus, the bacterial proteins that are directly involved in this process 
are the most common targets of a colonization prevention vaccine. These include the 
flagellar components FliC and FliD, the adhesin Cwp66 and the Cysteine Protease Cwp84(99–
101), which have all been tested along with canonical adjuvants in the most commonly used 
animal models of CDI (Table 1). In an animal model of infection, vaccinations of flagellar 
preparation and Cwp84 were found to decrease the number of colonized animals. It is 
important to note that this approach rarely provides protection from acute disease, but aims 
to prevent the initial acute episode itself. The carbohydrate capsule surrounding C. difficile is 
another emerging target for vaccine development. Recent advances in glycoproteomics have 
identified three unique carbohydrate signatures on the surface of C. difficile, all of which are 
moderately immunogenic(54). The challenge with carbohydrate antigens is the issue of 
accessibility and epitope masking, which all but ensure that antibodies against the specific 
signatures would require an adjuvant to assist in binding their cognate antigens. 
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Table 1: Summary of Surface Associated Antigens and Vaccine Candidates  
Antigen Method of 
Immunization 
Adjuvant Animal Model References 
Crude SLP Intraperitoneal, 
Intranasal 
Alum/CT Mice, Hamster (148) 
SLP. FliD, Cwp84 Intranasal, 
Intragastric 
Freund/CT Mice (99) 
Cwp84 Subcutaneous, 
Rectal, Intragastric 
Freund/CT Hamster (100) 
Cwp84 Intragastric/ Pectin 
Bead Encapsulation  
None Hamster (101) 
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1.7.1.2 Toxins as Immunogens 
 
The field of toxin based vaccines is considerably more crowded, with most antigen 
formulations targeting the toxins borrowing their rationale from the success seen with 
similar toxins in other bacterial species, like Clostridium tetani(102)The relative success of 
antitoxin vaccines is based on protection from symptomatic illness, with a further metric of 
success being protection from recurrent disease.  
Initial efforts used formalin inactivated toxins as the vaccine antigen, and showed 
protection from fulminant disease in a hamster model(94). Subsequent studies have 
optimized the method of delivery, use of adjuvants and preparation of the antigen. Pilot 
studies in small human cohorts were successful, with most participants developing serum 
antibody titers and a significant percentage also developing mucosal antibody titers with 
Alum as an adjuvant. These antibodies showed good in vitro neutralization capacity as 
well(94).  
Acambis developed and conducted a Phase I clinical trial with a ‘second generation’ 
antigen preparation, consisting of highly purified formalin inactivated, alum-adsorbed toxins 
also demonstrated good tolerance and safety(94). However, the degree of seroconversion 
was slightly lower, especially for TcdB. This vaccine was then further developed by Sanofi-
Pasteur, and tested in a Phase II trial, the results of which recapitulated a weaker response 
to TcdB, which required a booster 6 months post the first vaccination(98). Phase III studies 
evaluating the immunogenicity and efficacy in aging individuals (>50 years of age) are 
ongoing.  
Other strategies have been used in newer vaccines. The ClosTron system(6), a tool for 
forward and reverse genetics of C. difficile has been used to great effect by Pfizer, to develop 
a genetically modified full length toxoid based vaccine in a toxin-deficient strain(55). Phase I 
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studies have been completed with good tolerance, and two Phase II studies are currently in 
progress, evaluating efficiency in adults aged 50-85 years.  
The final vaccine currently in clinical trials was developed by Valneva. This 
formulation uses a recombinant fusion protein containing the C-terminal receptor binding 
domains of both toxins, with a small linker peptide between them. Efficacy has been 
evaluated with and without alum. Phase I studies have shown a good tolerance and safety 
profile, and a significant and long lasting antibody titer, in young adults and aged adults(56). A 
phase II trial is currently underway. These findings have been summarized in Table 3. 
There has been significant progress in the field of experimental vaccine delivery 
platforms, with multiple DNA vaccines currently in preclinical phases (Table 2). DNA vaccines 
have evolved in recent years, and rapid strides in vaccine delivery technology indicate that 
the platform may soon reach the mainstream. Simultaneous advances in delivery 
technology(103, 104) and synthetic techniques for the more efficient production of DNA 
immunogens have fueled this progression. The DNA platform is ideal for the induction of 
monoclonal antibody responses to immunogens(105). The advantages DNA vaccines offer lie 
primarily in their cost effectiveness and ease of manufacture, but also extend to their 
potential for combinations and the easy inclusion of molecular adjuvants to boost the 
immune response to them. Their disadvantage, historically has been the relatively limited 
induction of a humoral response, as compared to the strong T-cell response they engender. 
In recent years, the humoral induction has been drastically improved, with strong, durable 
antibody responses elicited by DNA vaccines(106–111),(81) .  
DNA vaccines have been tested in the context of aging models, and a variety of 
infections. An antimalarial DNA vaccine was found to have impaired antibody and T cell 
responses, and subsequently reduced protective capacity after 3 immunizations in aged 
mice(112). Vaccination of aged mice with an influenza vaccine was found to generate a weaker 
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serum antibody response, but a protective cytotoxic T lymphocyte (CTL) response from 
homologous strains of the virus(112). In a different study, CpG-DNA was used as an adjuvant 
to boost the immune response to DNA vaccines against Trypanosoma cruzi and Bordetella 
pertussis, this adjuvanted immunization was capable of generating a ‘young-like’ response in 
aged mice(113). Taken together, these studies indicate that DNA vaccines have potential for 
use in the immunosenescent, and also highlight the potential for adjuvants in boosting the 
immune responses in the elderly. 
 In the context of CDAD, the receptor binding domain (RBD) is the popular antigen of 
choice for DNA vaccines, with at least three separate groups publishing promising 
results(81),(114),(115). Our laboratory developed and tested a highly optimized DNA vaccine to 
the RBD of tcdA and tcdB, delivered 3 times intramuscularly with in vivo electroporation. 
Vaccination induced a strong, durable antitoxin IgG response in mice and nonhuman 
primates. This humoral response protected mice from lethal challenges of two strains of C. 
difficile, including the hypervirulent UK1 strain. Serum antibody was also capable of 
neutralizing C. difficile toxins ex vivo(106).   There is a strong possibility of a DNA vaccine to C. 
difficile entering the clinic, and the previously characterized DNA vaccine developed in our 
laboratory is one candidate, as it has been shown to elicit a strong, protective antibody 
response, without the usage of adjuvants, in mice and nonhuman primates(81).  
In conclusion, the challenges that the field is currently facing revolve around the 
need to develop vaccines formulated specifically for at-risk populations like the aging that 
have underlying immune suppression that poses a challenge for low response, thus a need 
for adjuvants and optimized delivery platforms. These vaccines would need to generate 
strong humoral responses that are durable, and it is foreseeable that experimental vaccine 
platforms like DNA vaccines will be instrumental in achieving this goal. 
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Table 2: Summary of Vaccines in Preclinical Testing 
Antigen Vaccine 
Platform 
Vaccination 
Regimen 
Adjuvant Animal Model Immune 
Response 
Measured 
References 
Purified 
Toxoid A and 
B 
Protein Parenteral Cholera 
Toxin 
Hamster Antitoxin 
IgG 
Torres et 
al,1995 
Genetically 
Modified 
Toxoid A and 
B 
Protein Intramuscular None Hamster Antitoxin 
IgG 
(55) 
Recombinant 
fusion of RBD 
of TcdA and 
TcdB 
Protein Intramuscular Alum Mouse, 
Hamster,NHP 
Antitoxin 
IgG 
(149) 
tcdA-
RBD+tcdB-
RBD 
DNA Intramuscular+EP EP Mouse, 
Guinea pig, 
NHP 
Antitoxin 
IgG 
(81) 
Fusion of 
tcdA-RBD and 
tcdB-RBD 
DNA Intraperitoneal None Hamster Antitoxin 
IgG 
(114) 
tcdA-RBD DNA Intramuscular/ 
Intramuscular+EP 
EP Mouse Antitoxin 
IgG 
(115) 
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Table 3: Summary of Vaccines Tested in Clinical Studies 
Antigen Clinical Trial Vaccination Regimen Adjuvant References 
Partially purified Toxoid A 
and B (Acambis) 
Phase I 
 
4 doses i.m/healthy 
adults  
Al(OH)3/none (94, 95) 
Highly purified Toxoid A 
and B (Sanofi Pasteur) 
Phase I  
Phase II 
3 doses i.m/healthy 
adults 
3 doses i.m/elderly, at 
risk 
Al(OH)3 (97) 
Genetically modified full 
length TcdA and TcdB 
(Pfizer) 
Phase I 
Phase II 
 
3 doses i.m/healthy 
adults 
3 doses i.m/elderly, at 
risk 
None NCT01706367 
Recombinant fusion 
protein (Valneva) 
Phase I 
Phase II 
3 doses i.m/healthy 
adults, at risk, elderly  
None (56) 
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1.7.2 Passive Immunization Strategies 
 
Passive immunization offers an alternative approach to target CDAD, as a 
supplement to active immunization strategies, or even as a therapy on its own. The potential 
for a viable passive immunotherapeutic is strengthened by the rapid advances made in 
relevant technology. These new technologies effectively permit cheaper and more efficient 
generation of monoclonal antibodies, the main component of a successful passive 
immunotherapeutic. They offer a convenient alternative to traditional hybridoma 
techniques, which have historically been prohibitively expensive and sensitive.  
Passive immunity of this sort is an attractive option for specific demographics, namely aging 
and immunosuppressed patients. At risk of developing severe and recurrent CDAD, these 
patients are unable to mount an immune response of significant strength and specificity to 
handle the disease. Ostensibly, they would benefit from infusions of preformed antibodies 
to manage recurrent disease. 
 1.7.2.1 Antitoxin Monoclonal Antibodies 
  
Multiple monoclonal antibodies against the toxins or fragments of the toxins have 
been raised in humanized transgenic mice(116). These antibodies were then tested in a 
hamster challenge model, where they protected from fulminant disease(117).  Actoxumab 
(formerly called CDA1) and Bezlotoxumab (formerly called CDB1) are the most well studied 
monoclonal antibodies(117), that bind to the receptor binding domain (RBD) of TcdA and TcdB 
respectively.  Phase I and Phase II clinical trials evaluating the safety and efficacy of these 
antibodies have shown very promising results(118),(119). Functionally, Actoxumab showed 
direct toxin neutralization that did not depend on antibody effector functions(120).  There was 
a significant decrease in the recurrence of CDAD in contrast to standard-of-care antibiotic 
therapy, but little to no effect on acute infection. The most interesting result was the fact 
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that administration of Bezlotoxumab alone was effective in controlling recurrence, while a 
combination of both antibodies did not increase efficacy.  
As mentioned earlier, the biggest hurdle to adopting monoclonal antibodies as a 
therapy on their own remains the large cost of production and complicated process of 
production(121). Advances in technology have not been fast enough to replace the original 
method of generating monoclonal antibodies, the usage of hybridomas(122). Specialized 
reagents and mycoplasma free culture environments are both essential to the production 
and maintenance of hybridomas. Scaling these conditions to the size and standards of good 
manufacturing practices has proven to be expensive, in turn raising the price of these 
antibodies in the commercial market.  The only alternative to this method is the usage of 
expensive transgenic mice and hamsters as a source of antibodies, which is also an 
expensive undertaking(123). 
DNA encoded monoclonal antibodies offer a unique, cost effective and powerful 
solution to this problem. This technology relies on the transformation of cells at the site of 
injection with plasmids expressing a full length monoclonal antibody of tailored specificity, 
relying on a secretory leader sequence to ensure that the assembled antibody is secreted 
from the cell where it can exert its function. Potentially, with an optimal delivery method, 
every transformed myocyte can secrete an endogenous, highly specific monoclonal antibody 
that can immediately enter the circulation and exert its function as and when it encounters 
its cognate antigen. This technology has been used successfully in a preclinical study testing 
efficacy of protection of a monoclonal antibody against the envelope of the Chikungunya 
virus, with strong data supporting the validity of the platform(124). Karuppiah et al display 
evidence that a single immunization with a plasmid encoding a full length IgG against the 
envelope glycoprotein of Chikungunya virus or an Fab fragment against the same antigen 
was protective from a challenge with Chikungunya isolates. (124) Flingai et al(125) demonstrate 
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the usage of this technology as protective from dengue virus infections. This study used DNA 
encoded monoclonal antibodies that neutralized the virus in vivo.  
The studies referenced here have described the unique challenges associated with 
the development of vaccines for the elderly. Here, we test our previously developed DNA 
vaccine to the RBD of C. difficile toxins A and B in an aging murine model. We hypothesize 
that vaccination will elicit a functional immune response in aging animals, which is of a lower 
magnitude than young mice. We also test the protective capacity of this vaccine in a 
challenge model. Secondly, we describe the design and development of DNA-encoded 
monoclonal antibodies targeting the two toxins of C. difficile, and test their expression and 
specificity in vitro and in vivo. We propose their usage as immunotherapeutics that could 
potentially alleviate the acute symptoms of CDAD by their immediate acting toxin 
neutralization functional capabilities.   
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2.1 Abstract 
 
C. difficile infection (CDI) is among the most frequent Hospital Acquired Infections in 
the US and most of the developed world(39, 41, 43). CDI is particularly prevalent in the elderly 
population (>65 years of age), with incidence, disease severity and recurrence, as well as 
associated mortality sharply increasing in this high-risk demographic. CDI is primarily 
mediated by two large enterotoxins, A and B, which glycosylate Rho proteins, and cause 
actin disruptions and intestinal cell death. Our laboratory has previously developed a DNA 
vaccine to elicit a humoral response to the C-terminal receptor binding domains (RBD) of 
these two enterotoxins, subsequently providing active protection in a lethal orogastric spore 
challenge murine model of CDI. However, the immunogenicity of this vaccine has yet to be 
tested in the context of an aging immune system. Here, we hypothesize that immunization 
with tcd A-RBD/B-RBD vaccine will elicit a lower, but protective, functional antitoxin humoral 
response in aging mice when compared to young adult mice, and protect against a lethal C. 
difficile spore challenge. Young adult (6-8 weeks) and aged (18-22 months) C57BL/6 mice 
were immunized with tcd A-RBD/B-RBD followed by in vivo electroporation twice, 2 weeks 
apart, and serum and mucosal anti-toxin antibody levels were measured by ELISA post final 
immunization and prior to challenge with a lethal dose of C. difficile VPI 10463 strain spores.  
The functionality of the antibodies was measured using an ex vivo toxin neutralization assay, 
and quantified using a caspase activation assay. Bacterial burdens in young and aged animals 
were measured, and immunized animals were found to have a lower burden when 
compared to controls. Aged animals had a significantly higher load of bacteria than young 
animals. These data indicate that older animals developed a weaker humoral response to 
the vaccine, but can neutralize C. difficile toxins ex vivo. In conclusion, the tcd A-RBD/B-RBD 
vaccine is protective in aging animals and could be developed for testing in at risk elderly 
individuals. 
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2.2 Introduction 
 
C. difficile is a Gram positive sporulating bacterium(2) that causes gastrointestinal disease, 
with the symptoms of infection ranging from diarrhea to pseudomembranous colitis(3) and 
toxic megacolon(16), which are often fatal. A CDC funded study estimated that there were 
approximately 453,000 cases of, and 29,000 deaths due to, CDI in 2011 alone(43). The disease 
also costs the healthcare system an estimated $8 billion annually, making it a highly relevant 
public health problem(44). In addition to being the leading cause of antibiotic-associated 
diarrhea, CDI is a potent problem in the elderly. The likelihood of developing recurrent CDI is 
10-fold higher in individuals greater than 65 years of age(41). This increased risk is explained 
by the weaker immune response in the aging population, as well as other factors like pre-
existing health conditions and microbiome composition(39). CDI is a disease that requires an 
ablation of the microbiome, and is therefore associated with use of antibiotics as well as 
gastrointestinal surgery, both of which are known to cause alterations and imbalances in the 
gut microbiome.   
The bacterium produces two large exotoxins, called toxin A and toxin B, or tcdA and 
tcdB, which are the primary mediators of mucosal disease. These toxins exert their function 
by entering intestinal epithelial cells by receptor mediated endocytosis and glycosylating G-
Protein Coupled Receptors (GPCRs), specifically the Rho and Rac superfamilies. This 
glycosylation causes actin cytoskeletal rearrangements, resulting in cell death and 
detachment of tight junctions(18). 
 There is currently no licensed vaccine against C. difficile or its toxins. However, 
several vaccines targeting the toxins are currently in various stages of clinical development, 
with a specific focus on generating an immune response in aging individuals. In addition to 
traditional protein immunogens, which are typically formulations of inactivated toxin or 
recombinant peptides of the toxin, non-conventional vaccine platforms may hold the key in 
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developing a safe, immunogenic, and protective vaccine against CDI. The DNA vaccine 
platform is one such non-traditional method, that has attractive potential in this context. 
DNA vaccines are cost effective and historically have been well tolerated and safe. In 
addition, they are highly versatile, with extremely flexible antigen design being one of the 
strengths of the platform. Our laboratory has previously developed a DNA vaccine eliciting 
humoral immunity to the C-terminal Receptor Binding Domain (RBD) of the two toxins A and 
B, which has shown immunogenicity and protection in a murine model of CDI(106). These 
antigens are largely similar in both toxins, and have been targeted by multiple vaccines(56, 81, 
114, 115). Sequence alignment of the toxin loci in multiple strains of C. difficile has also revealed 
that these domains are largely conserved across multiple strains(38), further validating their 
choice as a target antigen. 
However, this vaccine is yet to be tested in an immunosenescent animal model, 
which would enhance its clinical relevance, given the epidemiology of the disease. Our 
laboratory has developed an immunosenescent animal model of CDAD. We have established 
that aged animals are more susceptible to a challenge with C. difficile spores than young 
mice. A dose of spores that was sublethal in young mice was found to cause significant 
mortality in aged mice. In addition, we have shown that there is an impaired antitoxin 
humoral response that is caused by reduced numbers of germinal center B-cells and TFH 
cells, and impaired co-stimulation of B-cells (unpublished data, Bernui and Kutzler).  Here, 
we test this DNA vaccine in our aging murine model, to evaluate its efficacy and 
immunogenicity in a senescent immune system.  
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2.3 Methods 
 
2.3.1 Cell culture 
 
HEK-293T/17 (ATCC CRL-11268) and Vero 76 (ATCC CRL-1587) cells were cultured in 
complete growth medium (Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum and 1% antibiotic-antimycotic). Cells were incubated in a 5% CO2 
humidified incubator at 37˚ Celsius.  
2.3.2 Animals 
 
Six-to-eight-week-old (young adult) and eighteen to twenty-two-month-old (aged) male and 
female C57BL/6 mice (Jackson Laboratories, Bar Harbor, ME and NIA, Bethesda, MD)) were 
housed in a temperature-controlled, light-cycled, specific-pathogen free facility at Drexel 
University College of Medicine, Philadelphia, PA. All animal work and in vivo electroporation 
of DNA vaccines in mice was conducted in accordance with the guidelines set forth by the 
National Institutes of Health and performed under protocols approved by the Institutional 
Animal Care and Use Committee at Drexel University College of Medicine (IACUC and 
Biosafety protocol 20474). 
2.3.3 Plasmid immunization and in vivo electroporation  
 
Plasmids were formulated in 0.25% bupivacaine-HCl (Sigma, St. Louis, MO). Groups 
of 7 mice were immunized either with 10 μg of the control plasmid (pVAX1) or 10 μg each of 
the antigenic plasmid (pARBD-NQ and pBRBD-NQ) in a volume of 20 μl twice, two weeks 
apart. The mice were isofluorane-anesthetized during vaccination.  All immunizations were 
administered into the tibialis anterior muscle of the left hind limb with an insulin syringe, 
and immediately followed by in vivo electroporation (CELLECTRA 2000, Inovio 
Pharmaceuticals, Blue Bell, PA). This process requires the placement and application of a 
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three-pronged array around and into the site of immunization, pulsing 0.2 A twice, delivered 
for 52 ms/pulse and separated by 1 second. 
2.3.4 Challenge with C. difficile spores 
 
Young (six-eight week old) and aged (eighteen to twenty-two months old) C57BL/6 
mice were immunized twice and fed an antibiotic cocktail comprising of Clindamycin, 
Colistin, Gentamicin, Kanamycin and Vancomycin infused in water for 4 days. The mice 
received an intraperitoneal injection of Clindamycin on the fifth day(126, 127), and then 
received an orogastric challenge of a lethal dose (105 cfu/ml) of C. difficile strain VPI 10463. 
They were then monitored for weight loss, morbidity and mortality for a period of 7-10 days, 
and moribund animals were euthanized.  
2.3.5 Serum isolation 
 
Blood was obtained 7 days post 1st and 2nd immunization by submandibular 
bleeding, and by cardiac puncture and exsanguination at the time of euthanasia. The blood 
was then separated in serum gel tubes containing heparin and the serum fraction was 
collected and used for further analysis. 
2.3.6 Analysis of serum antibodies  
  
Enzyme Linked Immunosorbent Assays (ELISAs)(128) were used to quantitate the 
humoral immune response to vaccination in serum. Ninety-six well plates designed for 
EIA/RIA (Costar, Thermo Fisher, Waltham, MA) were coated with 0.5 μg/ml recombinant C. 
difficile RBD A or RBD B (as described in Baliban et al(106),(129)) for 24 hours. Two rows of these 
plates were coated with serial dilutions of a recombinant mouse IgG antibody (Santa Cruz 
Biotechnology, Santa Cruz, CA) starting at 5000 ng/ml, diluted 2-fold across the plate. 
Coated plates were washed and non-specific binding was blocked for 2 hours at room 
temperature with 5% BSA in PBS-T (PBS+0.05% Tween 20). Serum from vaccinated animals 
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was diluted in blocking buffer (5% BSA in PBS-T) and incubated at room temperature for 2 
hours. Bound antibodies were detected by addition of horseradish peroxidase-conjugated 
secondary antibodies. All secondary antibodies were used at a 1:10,000 dilution in blocking 
buffer, and incubated for 1-2 hours at room temperature. Plates were washed and 
developed with a chromogenic substrate, 3,3’,5,5’-Tetramethylbenzidine (TMB, 
ThermoFisher Scientific,). The chromogenic reaction was stopped with 2N H2SO4, and the 
absorbance at 450 nm was read using an EL 312 Bio-Kinetics microplate reader (Bio Tek 
Instruments Inc., Winooski, VT). Antibody levels were interpolated from OD values based on 
the absorbance readings obtained from the standard curve (mouse IgG).   
2.3.7 In vitro cell rounding assay 
 
The minimum concentration of Tcd A and Tcd B that induces 100% cell rounding and 
death was determined using Vero cells. 5.0 x 104 Vero cells were seeded in ninety-six well 
plates 24 hours prior to the assay. C. difficile toxins A and B (List Biologicals, Campbell, CA) 
were diluted in medium replete with 5% FBS, starting at a concentration of 2 μg/ml. The 
plate was imaged using an Olympus IX81 microscope 24 hours post addition of the toxins, 
and the percentage of cell rounding was noted. Apoptosis was quantitated with a 
CaspaseGlo 3/7 Assay(130) (Promega, Madison, WI). 
2.3.8 CaspaseGlo 3/7 Assay 
 
The commercially available CaspaseGlo 3/7 kit, which measures apoptosis through 
the cleavage of a tetrapeptide by effector/executioner caspases that results in a luciferase 
reaction was used to quantify cell death(131). The kit was reconstituted at room temperature. 
30 μl of the assay buffer was added to a plate being tested for cell rounding. The plate was 
then incubated in the dark for 1 hour at room temperature, and read on a GloMax 
microplate luminometer (Promega, Madison, WI).   
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2.3.9 Ex vivo toxin neutralization assay 
 
The functionality of the serum from immunized animals was analyzed using an ex 
vivo toxin neutralization assay. Serial dilutions of serum were co-incubated with a 
concentration of toxin twice that which was needed to yield 100% cell rounding at 37˚ 
Celsius for 1 hour. This mixture was then added to a monolayer of Vero cells. Cell rounding 
was visualized using an Olympus IX81 microscope 24 hours post addition of the serum and 
toxins. Apoptosis was then quantitated using a CaspaseGlo 3/7 Assay. The readout from the 
CaspaseGlo 3/7 assay was normalized to the assay controls, with the positive control 
readout being 100% neutralization and the negative control being 0%. This method was then 
used to express the neutralizing capacity of the serum samples tested as a percentage. 
2.3.10 Enumeration of bacterial load in intestinal contents 
 
The intestinal contents of mice that were immunized and challenged were collected 
at the time of their sacrifice. A loopful of stool was weighed and serially diluted in PBS and 
10 μl of each dilution was added to a petri dish containing Brain Heart Infusion Agar, 
supplemented with C. difficile supplement (Thermo Fisher, Waltham, MA), taurocholate and 
10% L-Cysteine, a culture medium selective for C. difficile.. The inoculated plates were then 
incubated in an anaerobic chamber (PLAS Labs, Lansing, MI) for 24 hours in a <0.01% O2 
environment and colonies were counted. The number of colony forming units per gram was 
calculated and graphed. 
2.3.11 Data and statistical analysis 
 
All data analysis was performed on Prism 6 (GraphPad, San Diego, CA). Two-way 
ANOVAs, non-parametric Kruskall-Wallis tests, Holm-Sidak test, Kaplan-Meier analysis and 
Mantel-Cox tests were used to compare results between groups. All results were presented 
as Mean+SEM of the 6 or 7 animals per group. 
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2.4 Results 
 
2.4.1 Vaccination with pARBD-NQ and pBRBD-NQ elicited a lower humoral response 
in aged mice than young mice 
 
The immune response to vaccination in senescent mice has been documented to be 
weaker and less effective than immunocompetent mice, with a 16-fold lower antigen-
specific antibody  response after three immunizations(132). Mechanistically, these defects 
have been associated with impaired B cell co-stimulation by OX40 and CD40L, leading to 
lower affinity antibodies that are unable to overcome infection(91, 133). This remains one of 
the challenges with vaccine development in the aging population. Adjuvants could 
potentially be used to boost the response to a vaccine(113), but it is pragmatic to examine the 
immune response to the vaccine on its own, as a means of establishing a baseline.  
To this effect, we hypothesized that, in the aging mouse model, vaccination with 
pARBD and pBRBD would induce a lower, but functional and protective, humoral immune 
response, as compared to young adult mice.Young and aged mice (N=7) were immunized 
twice intramuscularly with 10 μg each of pARBD and pBRBD, or 10 μg of pVAX1 along with in 
vivo electroporation. Immunizations were two weeks apart. Animals were bled 7 days post 
each immunization. (See Figure 2-1 A). Levels of serum anti-RBD antibodies were measured 
by ELISA. At day 7 post 2nd immunization, we found that aged mice had a markedly lower 
serum IgG level than young mice, while control mice that received pVAX1 had a negligible 
response, as expected (Figure 2-2). To determine the extent of antibody content, the end-
point titer(134) of antigen specific IgG for both young and aged mice was calculated in an 
ELISA, and defined as the point at which absorbance at 450nm was twice the absorbance of 
pVAX1 immunized animals. The endpoint titers of aged mice were found to be 25600. Young 
mice had a titer of 204800 (Figure 2-3).  
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   In agreement with the results reported by Baliban et al(106), we found no detectable 
serum IgA at day 7 post 2nd immunization (data not shown). The delivery of our DNA vaccine 
sans adjuvant was capable of generating a strong humoral response. We next aimed to 
evaluate the functionality of the antibody elicited by immunization.   
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A) 
 
B) 
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Figure 2-1 A) Immunization Schedule:  Young and aged mice (N=7) were immunized twice 
with 10 μg each of RBD-A and RBD-B or 10 μg pVAX1, 2 weeks apart. Mice were bled 7 days 
post each immunization to detect serum antibody levels. They were then rested for a month 
before receiving a lethal dosage of C. difficile VPI 10463 spores. B) Design of Vaccine 
Constructs: Plasmids encoding the C-terminal receptor binding domain (RBD) of toxins A and 
B of C. difficile were synthesized, with the RBD gene being inserted downstream of a CMV 
promoter, Kozak sequence and secretory IgE sequence. The plasmid backbone was the 
pVAX1 vector, optimized for DNA vaccine delivery. Putative glycosylation sites on the RBD 
were mutated to prevent their glycosylation by transfected cells.  
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Figure 2-2 Aged mice generated a weaker humoral response when immunized with tcdA-
tcdB RBD:  Serum IgG levels in mice that were immunized twice with pARBD and pBRBD or 
pVAX were measured by ELISA. ELISA plates coated with recombinant RBD protein were 
blocked for nonspecific binding and incubated with serum from immunized animals. Bound 
antibodies were quantified by the usage of HRP-conjugated secondary antibodies and TMB 
as a chromogenic substrate. Multiple t-tests comparing RBD A-Old and Young, and RBD B-
Old and young were performed, and a p value<0.001, obtained from the Holm-Sidak test. 
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Figure 2-3 Aged mice generated a lower endpoint titer when immunized with tcdA-tcdB 
RBD : Young and aged mice were immunized twice with 10 μg each of RBD-A and RBD-B or 
10 μg of pVAX1. Mice were bled at day 7 post 2nd immunization and the extent of antibody 
present in the serum was measured by determining the endpoint titers, defined as the 
dilution at which absorbance of serum from immunized animals was twice that of pVAX 
animals. Each point on the graph is the mean+SEM of 4 mice. 
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2.4.2 Vaccination with pARBD-NQ and pBRBD-NQ induced functional antibodies in 
aging mice 
 
We next aimed to validate the functionality of the antibodies elicited by our vaccine. 
The functional test we chose to use was an ex vivo toxin neutralization assay, where the 
capacity of antibodies to neutralize toxins and abrogate their effects on a monolayer of Vero 
cells was measured. We hypothesized that older mice would lose their neutralizing capacity 
at a lower dilution than young mice, as measured by a caspase activation(135) assay.  
Purified C.difficile toxins were titrated in a separate experiment, in order to 
determine the minimum dilution at which they caused complete cell rounding of a 
monolayer of Vero cells. This rounding was observed under a microscope and quantified 
using the CaspaseGlo 3/7 activation assay (Promega). The minimum rounding concentration 
(MRC100) was determined to be 6.25x10-2 μg/ml of toxin A and 9.7625x10-4 μg/ml of toxin B. 
Serum from immunized animals was diluted and incubated with 4 times the MRC100 to 
account for dilutions within the experiment and the avidity of the IgG antibodies within the 
serum at 37˚ Celsius. This mixture was then added to a monolayer of Vero cells for 24 hours. 
The monolayer was examined under the microscope and the degree of neutralization of 
toxin was measured by the CaspaseGlo assay. pVAX animals were used to provide a baseline, 
and to account for background neutralization. Some wells received no serum and served as a 
negative control, and serum from a survivor of primary infection with C.difficile spores was 
used as a positive control.    
Our results indicate that antibodies from aged mice are functional, showing good 
neutralizing capacity that is comparable to young mice till a dilution of 1:6400. From this 
dilution until the endpoint titer (experimentally determined to be 1:25600 for both toxin A 
and toxin B), we saw a steadily decreasing degree of neutralization. At the endpoint titer, 
there is no functional protection from the toxins, with the degree of neutralization 
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approaching the background protection imparted by control vaccinated mice Figure 2-4 A 
and Figure 2-5 A. Positive control (survivor) serum showed complete neutralization at all 
dilutions tested. The average neutralizing capacity of old and young groups was analyzed 
and represented in Figure 2-5.  
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Figure 2-4 The antitoxin A humoral response in aged mice is functional :   The neutralizing 
capacity of serum from 6 individual mice (3 young and 3 old) that received 2 immunizations 
was measured to evaluate functionality of the antibodies elicited. Serial dilutions of serum 
were co-incubated with a concentration of toxin A (Figure 2-4 A). 4 times the MRC100 and 
added to a monolayer of Vero cells. Serum from an animal that survived a primary infection 
with C. difficile spores was used as a positive control, and 9 wells were treated with no 
serum as a negative control. The CaspaseGlo 3/7 Assay was used to quantify the apoptosis 
caused by addition of toxin. 30 μl of CaspaseGlo 3/7 reagent was added to these cells and 
incubated for 1 hour before analysis on a Promega Glomax.  The readout from this assay was 
normalized to the positive and negative control and expressed as a percentage 
neutralization capacity. The average neutralizing capacity of the three mice was graphed in 
B). 
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Figure 2-5 The antitoxin B humoral response in aged mice is functional:   The neutralizing 
capacity of serum from 6 individual mice (3 young and 3 old) that received 2 immunizations 
was measured to evaluate functionality of the antibodies elicited. Serial dilutions of serum 
were co-incubated with a concentration of toxin B (Figure 2-5 A). 4 times the MRC100 and 
added to a monolayer of Vero cells. Serum from an animal that survived a primary infection 
with C. difficile spores was used as a positive control, and 9 wells were treated with no 
serum as a negative control. The CaspaseGlo 3/7 Assay was used to quantify the apoptosis 
caused by addition of toxin. 30 μl of CaspaseGlo 3/7 reagent was added to these cells and 
incubated for 1 hour before analysis on a Promega Glomax.  The readout from this assay was 
normalized to the positive and negative control and expressed as a percentage 
neutralization capacity. The average neutralizing capacity of the three mice was graphed in 
B). 
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2.4.3 Immunization with pARBD-NQ and pBRBD-NQ protected aged mice from a lethal 
spore challenge 
 
In previous studies in mice, guinea pigs and non-human primates, we showed that 
our DNA vaccine (pARBD-NQ + pBRBD-NQ) was immunogenic and protected from a lethal 
spore challenge with two different strains of C. difficile (VPI 10463 and hypervirulent 
UK1)(106). However, these animals were immunocompetent, young adults with a healthy 
immune response. The immunogenicity of this vaccine in immunocompromised or 
immunosenescent mice was left to be addressed. Here, we tested the protective efficacy of 
the vaccine in aging mice, which have a notably attenuated humoral response, by using a 
spore challenge with C.difficile strain VPI10463 spores. Male and female mice (both young 
adults and aged adults) were immunized twice with 10 μg each of pARBD and pBRBD or 10 
μg of pVAX, separated by two weeks. They were then rested for 30 days before being fed a 
cocktail of antibiotics including vancomycin and metronidazole in water for 72 hours. They 
were then injected intraperitoneally with clindamycin before being challenged orogastrically 
with a lethal dose (105 cfu/ml) of C.difficile strain VPI 10463 spores. The animals were 
weighed twice daily and monitored for morbidity and mortality (See Figure 2-5).  
Our results indicate that the vaccinated animals were protected from this infection, 
while the control animals succumbed at the peak of infection (~72 hours), as seen in Figure 
2-6 A). The change in weight post infection is a useful metric to examine the effect of the 
vaccination, with protected animals losing approximately 10% of their weight immediately 
after the challenge but recovering and regaining their weight over a week, while 
unprotected animals experienced a catastrophic slump in weight that fell below the Drexel 
University IACUC guidelines for euthanasia. Relative weight changes are displayed in Figure 
2-6 B). Finally, we measured the levels of anti-RBD antibody in serum from animals that 
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were immunized and challenged by ELISA. Our results show that older animals had a lower 
level of antibody than younger animals, but this was not a significant difference.  (Figure 2-
7). However, the results from our challenge indicate that this level of antibody was 
functional and sufficient to protect animals from a lethal dose of C. difficile spores. 
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Figure 2-5: Immunization and challenge scheme:  Mice were immunized twice intramuscularly 
with 10 μg each of pARBD and pBRBD or 10 μg of pVAX, two weeks apart. They were then rested for 30 
days. 6 days prior to challenge (day 38), they were fed antibiotics supplemented in water for 3 days, in 
accordance with the model described in Chen et al (126).  Mice were switched to antibiotic free water 
for 4 days. 24 hours prior to challenge (day 43), animals received an intraperitoneal injection of 
Clindamycin. On day 44 post the first immunization, animals were challenged orogastrically with 105 
spores of C. difficile strain VPI 10463. Mice were weighed twice daily and observed for morbidity for a 
 
A) 
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Figure 2-6 A) Immunization protected aged animals from a lethal challenge with C. difficile 
spores:  Mortality of animals that were immunized twice with pARBD and pBRBD or pVAX 
and rested for 30 days. They were then fed a cocktail of antibiotics for 48 hours, before an 
orogastrically challenged with 105 spores of C.difficile strain VPI10463. N=7 for all groups, 
one old mouse that received the vaccine succumbed to old age during the rest period. All 
control animals (pVAX) succumbed to infection at 72-96 hours post infection. Vaccinated 
animals were followed for 10 days before being euthanized. P Value <0.0001, Mantel-Cox 
test comparing survival of pVAX and RBD vaccinated animals.  
Figure 2-6 B) Weight change post immunization and challenge:  Relative change in weight 
of immunized animals post challenge. Animals were weighed twice daily. N=7 for all groups, 
one old mouse that received the vaccine succumbed to old age during the rest period. pVAX 
mice lost weight and were euthanized on day 3-4 in accordance with Drexel University 
IACUC standards. RBD vaccinated mice lost approximately 10% of their weight before 
recovering it by day 7. 
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Figure 2-7: Serum antibody levels in animals post immunization and challenge:  
Animals were immunized twice with pARBD and pRBD, or pVAX, and rested for 30 
days, fed antibiotics and then given a lethal dose of C.difficile VPI10463 spores. pVAX 
animals were euthanized at day 4 post challenge in accordance with Drexel 
University IACUC standards. Animals that were immunized with A-RBD and B-RBD 
were euthanized 10 days post the challenge. Serum obtained at the time of 
euthanasia was analysed by ELISA, and the levels of anti-RBD IgG were measured. A 
mouse IgG of known concentration was used to generate a standard curve from 
which antibody levels in the serum were interpolated.     
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2.4.4 Bacterial loads in animals protected from spore challenge 
 
Enumeration of the bacterial burden in a challenge model offers insight into the 
severity of disease, and thus, can be used to determine the efficacy of a vaccine. In theory, 
the protective efficacy of an antibacterial vaccine would vary inversely with the burden of 
bacteria cultured from the site of infection.  
Here, we analyzed the intestinal contents of the animals in the experiment, to 
enumerate the bacterial loads in each animal. Intestinal contents were obtained at the time 
of euthanasia, diluted in PBS and grown on petri dishes coated with brain heart infusion 
agar, a selective medium that was used to ensure that all colonies that were obtained after 
24-48 hours of anaerobic culture were of C. difficile. Colonies were small and possessed the 
shattered glass morphology most commonly associated with C. difficile. The number of 
colony forming units per unit volume was calculated, and differences between young and 
aged animals were observed. pVAX control mice, both young and aged, showed a 
significantly higher bacterial load than both young and aged animals that were immunized. 
Old animals showed a higher bacterial load than young animals in the immunized group as 
well, but this was not a statistically significant difference.  
The higher load in older animals could potentially be an indirect effect of the lower 
antibody titer elicited in older mice. The primary effect that C. difficile toxins have on the 
intestinal epithelium is the death and detachment of the epithelial barrier. This loss of 
integrity permits the action of both adhesins and the binary toxin, which increase adherence 
and attachment of the bacterium to the disrupted tissue, and permit the rapid replication of 
the bacterium. Immunized animals, which have antibodies capable of preventing this initial 
tissue disruption, would theoretically offer no surface for the bacterium to adhere to, 
replicate and thrive. While not a direct consequence of vaccination, this is a protective 
benefit that warrants further study in the context of vaccines against CDAD. In addition to 
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this, numerous studies have demonstrated a shift in microbiome composition with age, 
which may also contribute to creating a favorable environment for C. difficile(4). 
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Figure 2-8 Bacterial burden in aged mice was higher than young mice:  Intestinal contents 
of aged and young mice were obtained at the time of euthanasia. A loopful of intestinal 
contents was diluted in PBS and plated on BHI agar, supplemented with C. difficile 
supplement and taurocholare, and cultured in an anaerobic environment for 24 hours. 
Bacterial loads (expressed in CFU/ml) of all animals that were challenged with C. difficile 
spores in the experiment were obtained based on colony counts, and. *** denotes p <0.02, 
as measured by a Kruskall-Wallis test. Mean+SEM for 7 mice/group graphed.  
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2.5 Discussion 
 
CDAD is a swiftly escalating problem that is both a product of modern healthcare 
and current treatments for infectious diseases, and a cause of drug resistant infections(136). 
Given its etiology as a hospital acquired infection and its strong correlation with antibiotic 
usage, as well as the lack of a licensed vaccine, CDAD is a public health issue that needs an 
effective solution. Immunity to both toxins is needed for effective, long lasting protection, 
and remains the goal of most vaccines currently in development.   
The aging immune response is among the biggest conceptual challenges to vaccine 
design in the preclinical stage(57), and with a steadily aging population, the need for vaccines 
for the elderly, which elicit a strong and sustained immune response, will continue to grow. 
New strategies to overcome this hurdle are the need of the hour, and non-traditional 
vaccine platforms like DNA vaccines offer a safe, well tolerated and cheap option for a 
demographic that typically needs multiple booster immunizations.  
Here, we test the immunogenicity and protective capacity of a previously designed 
and optimized DNA vaccine encoding the receptor binding domains of C. difficile toxins A 
and B, in an aging murine model(81).The key finding from this work is the efficacy of the 
vaccine in aging mice, which have been documented to have a weaker immune response to 
vaccination and infection. The vaccine imparted 85% protection from a lethal challenge, 
which is particularly important in the absence of adjuvants to boost the immune response, 
indicating that the vaccine alone is sufficient to generate a protective antibody titer.  
Lower antibody titers that were functional and capable of neutralizing purified C. difficile 
toxins were seen in aged mice, implying that the titer of antibody necessary for protection 
from a lethal challenge is lower than previously thought. However, it is important to note 
that this study was conducted using a homologous strain of C. difficile (VPI 10463), which 
produces a median level of both toxins.  
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An interesting difference from previous studies is the greatly increased neutralizing antibody 
titers elicited by pBRBD-NQ. While lower, the titer of antibodies elicited by pARBD-NQ 
proved sufficient to protect animals from a challenge, providing evidence proving the 
hypothesis that the basal level of serum and mucosal antibody needed for protection is on 
the scale of nanograms/ml. The predominant isotype of antibody generated by the vaccine 
was IgG, which has been clinically validated as being the most relevant correlate of 
protection from CDAD(70). Serum antibodies from both young and aged mice that received 
two immunizations were capable of neutralizing toxins ex vivo at relatively low dilution 
factors, but the neutralizing capacity of serum from older animals sharply dropped with 
continued dilution, eventually showing no neutralizing ability at 1:25600, where young 
animals still had a detectable neutralizing antibody level.   
Another point of interest is the difference in bacterial loads cultured from old and 
young animals. As a vaccine that generates immunity to the exotoxins of the bacterium, the 
RBD DNA vaccine should theoretically have little to no effect on the load of bacteria in the 
gut. However, although older mice have a higher bacterial burden in general, animals that 
received the vaccine showed a significantly lower load than animals that received the 
control immunization. Factors contributing to this unexpected difference include the design 
of the infection model, protection from intestinal damage and an augmented immune 
response in vaccinated animals. In the infection model used in these studies, animals are fed 
antibiotics supplemented in the water they consume, for a period of 48 hours, to ablate 
their microbiome, permitting the germination of C. difficile spores. However, they are 
switched back to regular water 24-48 hours before the spore challenge. It is possible that 
this time is sufficient for a partial reconstitution of the microbiome, such that unchecked 
growth of C. difficile is inhibited.  
72 
 
The primary effect of a protective titer of antitoxin antibodies is the prevention of 
damage to the intestinal epithelium mediated by C. difficile toxins. The sustained integrity of 
the epithelium may provide a mechanical barrier to C. difficile, which typically replicates 
after adherence to the jagged, rearranged actin cytoskeletal elements of necrotic epithelial 
cells. This adherence is mediated by adhesins, flagella and by CDT, the binary toxin. Studies 
have reported the upregulation of C. difficile flagella in the context of a biofilm like state, 
which most commonly exists in the pseudomembranes that are a hallmark of late stage 
infections. Microanatomically, these pseudomembranes often contain large quantities of 
dead cells and are known to contain large quantities of CDT. In addition to this prevention of 
adherence, an intact epithelial lining may also be efficient in trafficking lymphocytes to the 
site of infection, recruiting another line of defense against the lethal effects of tcdA and 
tcdB.   
The protective efficacy in aged mice challenged with hypervirulent strains is yet to 
be determined, and is the next logical step in the preclinical testing of this vaccine. We plan 
on testing this by immunizing young and aged mice three times, separated by two weeks, 
and resting them for 3-4 months to ensure complete contraction of the immune response 
before challenging them with a lethal dose of the hypervirulent strain of C. difficile UK1. We 
anticipate that protective efficacy in this context will be slightly lower than with VPI 10463, 
owing to the greatly increased levels of toxins produced by the UK1 strain. Thus, in 
conclusion, we offer data validating our hypothesis that aged mice immunized with our DNA 
vaccine generated a lower, functional antibody response that protected them from 
challenge with a homologous strain of C. difficile.  
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3.1 Abstract 
 
C. difficile is a spore forming, gram positive bacteria that causes intestinal infections 
(CDI) that range from mild to fatal, depending on the immune response and intestinal 
microbiome of infected individuals. C. difficile associated disease (CDAD) is mediated by two 
large exotoxins A and B, which glycosylate Rho superfamily proteins and cause actin 
disruption and intestinal cell death. Recent findings suggest that passive immunotherapy has 
a key role to play in protection from CDAD. Toxin neutralizing monoclonal antibody (mAb) 
based treatment has been shown to be protective in immunocompetent and 
immunosenescent populations. The maintenance of protective levels of mAbs requires 
repeated immunizations, which are not feasible given the expense of generating mAbs. To 
reduce costs associated with treatment, we propose a DNA-based platform for generating 
fully functional human mAbs.  
 Here, humanized DMAbs specific for C. difficile toxin A and B were synthesized.  In 
vitro expression of antibodies was measured by ELISA. Longitudinal expression following in 
vivo delivery of DMAb into NOD SCID Gamma mice demonstrated rapid and sustained 
antibody levels over 21 days post single immunization. Furthermore, binding of DMAbs in 
sera from immunized animals to purified C. difficile toxoids was measured by ELISA, 
indicating that the antibodies elicited by immunization were antigen specific.  
These data validate the technology and design of DNA-encoded monoclonal antibodies 
targeting the receptor binding domain of C.difficile toxins A and B, and warrant further 
testing in an animal model of CDAD.  
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3.2 Introduction 
 
C. difficile is the most common healthcare associated infection in the United States, 
and most of the developed world(43). It is an expensive, evolving problem that is beginning to 
display altered epidemiology, with a growing number of infections arising outside of 
healthcare facilities(39). This sharp upturn in infections is indicative of a community wide 
problem, with most research concluding that recurrence of disease specifically is the true 
threat associated with C. difficile(137). The current standard-of-care treatment for CDI and 
CDAD alike is the usage of a cocktail of broad and narrow spectrum antibiotics. This regimen 
is a double-edged sword, as it ablates the microbiome of severely infected patients while 
eliminating their C. difficile load. The ablated microbiome then leaves the invalid susceptible 
to a renewed C. difficile infection. This cyclic process is the true cause of severe, recurrent 
CDAD. The deployment of fidaxomicin, a recently developed antibiotic that selectively 
eradicates C. difficile without much ablation of the microbiome has reduced these risks to an 
extent(138), but there remains a need for an effective therapeutic option that can alleviate 
symptoms of CDAD without increasing the risk of recurrence. 
Passive immunotherapy is an increasingly attractive avenue of investigation that has 
recently shown promising results in the milieu of C. difficile infections(117–120, 139). A recently 
published study in the New England Journal of Medicine reported the success of two Phase II 
clinical trials testing the efficacy of two fully human monoclonal antibodies, Actoxumab and 
Bezlotoxumab, that target tcdA and tcdB respectively. While having little to no effect on 
acute disease and illness, treatment with these antibodies reduced recurrence of infection 
by 16-17%. Interestingly, Bezlotoxumab alone was efficacious as compared to the placebo, 
with Actoxumab having little to no effect on outcomes(119). Monoclonal antibodies have 
been considered a potentially viable treatment option for CDAD for decades, but have been 
too expensive and difficult to produce on a large scale to be a realistic treatment option.  
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Recombinant human monoclonal antibodies have become slightly easier to produce 
in recent times, with humanized mice providing a stable and relatively economic solution, as 
compared to the traditional method of using hybridomas. While this is a welcome 
advancement, there remain numerous obstacles in the production of clinical doses of fully 
human monoclonal antibodies. 
DNA vaccines are currently undergoing a crucial phase in their development and 
adoption as a mainstream vaccine platform. The advantages the platform offers, most 
crucially the ease of production and low cost, make DNA vaccination particularly relevant to 
passive immunotherapy today. Numerous studies have showcased the induction of 
monoclonal antibodies by DNA immunogens, especially for proteins that are difficult to 
produce using recombinant technology(105). A new facet to this platform has been the design 
and usage of DNA plasmids that encode monoclonal antibodies against specific targets(124). 
Challenges to this approach have been the efficient assembly and trafficking of the antibody, 
and the design of plasmid constructs that code for all the components of an antibody. The 
incorporation of an IgE leader sequence and peptide self-processing sequences have largely 
ensured that a whole protein with the structural organization of an antibody is produced by 
all transformed cells.  The advantages traditionally associated with monoclonal antibodies, 
namely their exquisite specificity to target antigens are supplemented by the ease of 
customization that is a hallmark of the DNA vaccine platform, making these DNA-encoded 
monoclonal antibodies, or DMAbs, a viable therapeutic option. The technology has been 
validated in other studies, with DNA plasmids encoding monoclonal antibodies against the 
envelope glycoprotein of Chikungunya virus showing protective efficacy against a lethal 
challenge with live virus(124). Here, we describe the design and development of DNA-encoded 
monoclonal antibodies against the receptor binding domains of the two toxins of C. difficile, 
tcdA and tcdB.  
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3.3 Methods 
 
3.3.1 Cell culture 
  
HEK-293T/17 (ATCC CRL-11268) and Vero 76 (ATCC CRL-1587) cells were cultured in 
complete growth medium (Dulbecco’s modified Eagle’s medium supplemented with 10% 
fetal bovine serum and 1% antibiotic-antimycotic). Cells were incubated in a 5% CO2 
humidified incubator at 37˚ Celsius. 
3.3.2 Animals 
 
6-8-week-old NOD SCID Gamma (NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ) mice were obtained 
from the NSG breeding colony at the Wistar Institute and housed in a temperature and 
humidity controlled, light cycled, specific pathogen free facility at the Wistar Institute. All 
procedures and In vivo electroporation was performed in accordance with standards set by 
the NIH and the Institutional Animal Care and Use Committee at the Wistar Institute.  
 
3.3.3 Plasmid design and construction 
 
C. difficile toxin RBD monoclonal antibody sequences were obtained from patent 
application US2014120614 (A1) ― 2014-05-01. These sequences were then cloned into a 
DMAb plasmid as described in Muthumani et al(124). 
3.3.4 In vitro expression of plasmids  
4 μg of DMAb A, B or pVAX DNA was transfected into HEK 293T cells (0.5x106 cells in 
a 12-well plate) using GeneJammer (Agilent Technologies, Santa Clara, CA). 48 hours after 
transfection, culture supernatants were harvested and tested for presence of IgG from the 
DMAb plasmids.  
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3.3.5 Plasmid immunization and in vivo electroporation 
 
Groups of 4 mice each were immunized either with 100 μg each of DMAb A and 
DMAb B, 50 μg each of DMAb A and B, 100 μg of DMAb A alone, 100 μg of DMAb B alone or 
100 μg of pVAX1 as a control. All immunizations were administered into the tibialis anterior 
muscle of the left hind limb with an insulin syringe, and immediately followed by in vivo 
electroporation (CELLECTRA 2000, Inovio Pharmaceuticals, Blue Bell, PA). This process 
requires the placement and application of a three-pronged array around and into the site of 
immunization, pulsing 0.2 A twice, delivered for 52 ms/pulse and separated by 1 second  
3.3.6 Serum isolation 
  
Submandibular bleeds were used to extract blood on day 7, 14 and 21 post 
immunization. Serum was separated by centrifuging at 13,500 RPM for 15 minutes and 
analyzed for the presence of IgG via ELISA. 
3.3.7 Mucosal extract preparation 
 
Fecal pellets from individual mice were collected at day 7 and day 14 post 
immunization, and pooled for maximal output. Intestinal contents were obtained from all 
mice in the experiment at the terminal sacrifice on day 21. Pooled fecal pellets and intestinal 
contents were resuspended in fecal extract buffer, composed of 0.05% Sodium Azide, 0.05% 
Tween-20, 1% BSA and a cocktail of protease inhibitors (Complete protease inhibitor tablets, 
Roche, Nutley, NJ). This suspension was incubated on ice for 20 minutes, vortexing 
frequently. The solution was centrifuged at 13,200 RPM for 20 minutes. The supernatant 
obtained from this centrifugation was extracted and stored at -20˚ Celsius for further 
analysis.  
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3.3.8 IgG quantification ELISA  
 
High affinity ninety-six well Nunc Maxisorp plates (Thermo Scientific, Waltham, MA) 
were coated with 10 μg/ml of goat anti-human IgG Fc fragment (Bethyl Laboratories, 
Montgomery, TX) for 24 hours. Non-specific binding was blocked by incubating the coated 
plates with 200 μl of 10% FBS in PBS-T per well for 1 hour at room temperature. Primary 
samples (either serum, supernatant from transfected cells or mucosal extract) were applied 
at a 1:50 dilution for 1 hour at room temperature. Secondary antibodies conjugated with 
horseradish peroxidase were used to quantitate antibody levels in the ELISA. Goat anti-
human IgG ĸ light chain antibody (Bethyl Laboratories, Montgomery, TX) at a dilution of 
1:10000 for 1 hour at room temperature. They were then developed using freshly made O-
Phenylaminediamine (OPD) substrate (Sigma, St Louis, MO). Absorbance was read at 450 nm 
on a microplate reader (Bio-Tek, Winooski, VT).  
3.3.9 Analysis of serum and mucosal antibodies 
 
Serum antibodies were analyzed by ELISA. High-affinity ninety-six well plates 
designed for EIA/RIA (Thermo Scientific, Waltham, MA) were coated with 0.5 μg/ml of 
purified C. difficile Toxin A Toxoid and Toxin B Toxoid (List Biologicals, Campbell, CA) for 24 
hours. Non-specific binding was blocked by incubating coated plates with 200 μl of 5%BSA in 
PBS-T for at least 2 hours at room temperature. Serum, mucosal extract or supernatant from 
transfected cells was then added to the blocked plates at a dilution of 1:50, and allowed to 
incubate at room temperature for 2 hours at room temperature, or 24 hours at 4˚ Celsius. 
Horseradish peroxidase conjugated secondary antibodies were used to quantify the levels of 
antigen specific antibody in the serum or mucosal extract. Goat anti-human ĸ light chain 
antibodies (Bethyl, Montgomery, TX) were used at a dilution of 1:10000, and allowed to bind 
for 1 hour at room temperature. Plates were then developed using 3,3’,5,5’-
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Tetramethylbenzidine (TMB, Thermo Scientific, Waltham, MA). The chromogenic reaction 
was stopped with 2N H2SO4, and the absorbance at 450 nm was read using an EL 312 Bio-
Kinetics microplate reader (Bio Tek Instruments Inc., Winooski, VT). Antibody levels were 
analyzed using a standard human recombinant IgG run in parallel with serum samples.  
3.3.10 Data analysis 
 
All data analysis was performed on GraphPad Prism 6 (GraphPad, San Diego, CA). 
Paired and unpaired t-tests were used to analyze data obtained.    
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3.4 Results 
 
3.4.1 Design and construction of plasmids encoding monoclonal antibodies to the 
receptor binding domain of C. difficile toxins A and B 
 
Numerous monoclonal antibodies targeting the toxins of C. difficile have been 
developed and extensively tested, and published sequences of these antibodies are available 
on publicly curated databases like the National Center for Biotechnology Information (NCBI). 
The sequences of two antibodies, designated CDA-1 and CDA-2 (Medarex, Princeton, NJ) 
were obtained from patent application US2014120614 (A1) ― 2014-05-01, and the 
sequences of the heavy and light variable chains, that impart antigen specificity, were cloned 
into a plasmid that was previously optimized for expression of a fully assembled human 
monoclonal antibody(124).  
This was done by inserting a furin cleavage site and P2A self-processing peptide 
sequence to facilitate cleavage of the transcribed and translated protein. An IgE leader 
sequence was added upstream of the gene insert, to promote the trafficking of the gene 
product to the golgi complex, from where it is secreted out of cells. The entire plasmid was 
placed downstream of a CMV promoter, a common choice for DNA immunogens, and the 
plasmid was configured to produce an IgG1 antibody, although the source sequences were 
for IgG2 antibodies.   This designed plasmid was then synthetically manufactured and tested 
for expression and functionality. The design of the plasmid is described in Figure 3-1.  
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Figure 3-1: Design and construction of DMAb Plasmids:  An IgE leader sequence was 
inserted upstream of the coding regions for a human IgG1 antibody. A Furin cleavage site 
and P2A self-processing peptide was incorporated to facilitate the assembly of the separate 
chains into a single antibody. Sequences for variable regions were adapted from human 
monoclonal antibodies CDA-1 and CDA-2 (property of Medarex, Inc, Princeton, NJ). 
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3.4.2 DMAb plasmids are expressed and capable of binding to C.difficile antigens in 
vitro 
 
The designed plasmids for monoclonal antibodies against tcdA and tcdB were 
transfected into HEK 293T cells using GeneJammer, a polyamine formulation designed for 
transient transfection. Supernatants of transfected cells were harvested 48 hours post 
transfection. These supernatants were then analyzed by ELISA, to quantitate the amount of 
correctly assembled IgG produced by the transfected cells (Figure 3-2 A). Our results reveal 
that the antibody is efficiently processed and expressed in transfected cell supernatants, as 
seen in Figure 3-2, with 200-400 ng/ml of IgG being produced at 48 hours.  
We next analyzed the capacity of the IgG in these samples to bind to purified C.difficile 
toxoids in a binding ELISA. Supernatants from cells transfected with either DMAb A or DMAb 
B were added to plates coated with C.difficile toxoids A and B and blocked for nonspecific 
binding. Bound antibodies were quantified using HRP-conjugated secondary antibodies. Our 
results show that the monoclonal antibodies bound to their respective toxoid as seen in 
Figure 3-2 B. Supernatants from cells transfected with an empty vector (pVAX1) were used 
as a control, proving that there was no background binding of the antigen.  These data, 
showed that the DMAb plasmids expressed full length, correctly assembled IgG1 antibodies 
that were detectable by ELISA. These antibodies were able to bind to purified C. difficile 
toxoids.  
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Figure 3-2: DMAb Plasmids express fully formed antibodies that are capable of binding to 
C.difficile toxoids in vitro:  HEK 293T cells were transfected with either DMAb A, DMAb B or 
pVAX1, and supernatants were harvested 48 hours post transfection. A) IgG levels in the 
supernatant were quantified and their B) capacity to bind C. difficile toxoids were measured 
via ELISA. Ninety-six well plates were coated with 10 μg/ml of human IgG Fc fragment or 0.5 
μg/ml of C.difficile toxoid A orB for 24 hours and blocked for nonspecific binding. 
Supernatants were diluted 1:100 and added in duplicate for 1 hour at RT. Bound antibody 
was measured by HRP-conjugated secondary antibodies, and absorbance was read at 450 
nm. pVAX was used as a negative control. Means+SEM of 4 transfections were graphed. 
P<0.0001(****), P<0.05 (*) 
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3.4.3 A single immunization produces a persistent serum antibody titer in NOD/SCID 
mice 
 
Our next step was to analyze the expression of DMAb plasmids in a murine model, 
and the durability of the response that a single immunization could elicit. We used a 
NOD/SCID mouse model to perform these initial studies of the kinetics of expression, with 
the large-scale immunodeficiency seen in these animals serving to minimize interference 
from endogenous antibodies and immune components.  
There is some debate regarding the need for immunity to both toxins of C. difficile as 
a means of protection against disease. Numerous findings argue that immunity to either 
tcdA or tcdB alone is sufficient to protect from CDAD(26, 119). Here, we elected to immunize 
animals with plasmids encoding antibodies against both toxins. This was to examine any 
potential interference between the DMAbs themselves, and to measure the expression of 
the two plasmids in conjunction with each other. Groups of 4 animals received either 100 or 
50 μg of each plasmid, 100 μg of DMAb A alone, 100 μg of DMAb B alone or 100 μg of pVAX1 
as a control, in an intramuscular injection along with in vivo electroporation( See Figure 3-3 
A).  Serum was extracted at day 7,14 and 21 by submandibular bleeds and capture 
ELISAs were performed to quantify the amount of IgG in the serum. These results are 
presented in Figure 3-3 B. Antibody expression was detectable at day 7, peaked at day 14, 
and was maintained at a relatively constant level till day 21, when animals were euthanized. 
The group that received 100 μg of DMAb B alone had a significantly higher level than the 
groups that received both plasmids. Thus, we showed the presence of detectable antibody 
21 days post a single DNA immunization in a successful proof-of-concept experiment. The 
obvious caveat to make here is the usage of immunodeficient mice lacking the potential to 
generate auto-antibodies, which present a real and significant challenge to any potential 
passive immunotherapeutic. 
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Figure 3-3 A): Immunization Schedule:  Groups of 4 NSG mice were immunized and 
electroporated with 100 μg each of DMAb A and DMAb B, 50 μg each of DMAb A and B, 100 
μg of DMAb A, 100 μg of DMAb B, or 100 μg of pVAX1. They were then bled submandibularly 
at day 7,14 and euthanized at day 21. Intestinal contents were also collected at day 21, after 
euthanasia. 
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Figure 3-3 B) A single immunization with DMAb plasmids elicited an antibody response 
that was detectable till day 21:  NSG mice were immunized once with DMAb plasmids. 
Serum was obtained at day 7,14 and 21 post immunization. Ninety-six well plates were 
coated with 10 μg/ml of human IgG Fc fragment for 24 hours. Plates were blocked with 10% 
FBS for 1 hour at RT. Serum was diluted 1:50 and added in duplicate for 1 hour at RT. Bound 
antibody was measured by HRP-conjugated secondary antibodies, and absorbance was read 
at 450 nm. The mean+95% CI of 4 animals/group was shown. 
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3.4.4 IgG produced by immunization with DMAb was capable of binding purified C. 
difficile toxoids 
 
In CDAD, antibody-mediated protection is dependent on the neutralization of toxins 
released by the bacterium before they can bind to their cell surface receptors and exert their 
effects(70, 140). This neutralizing ability is therefore reliant on the binding of toxins by 
antibodies, and the potential usage of monoclonal antibodies in the treatment of CDAD 
hinges on the affinity of their interactions with C. difficile toxins(117). Therefore, we analyzed 
the antigen binding capacity of serum IgG produced by immunization with the DMAb 
plasmids via ELISA. Mice were immunized once with either 100 μg of both DMAb A and B, 
100 μg of one plasmid, 50 μg each of A and B, or pVAX. They were bled on days 7, 14 and 21. 
Serum from these animals was tested in an ELISA. Formalin-inactivated toxoids were used to 
measure the binding capacity of these antibodies. Our results show specific binding of toxoid 
A and B by serum from immunized animals (Figure 3-4).  
There is a high degree of conservation between the two toxins(141, 142). Some studies 
have postulated that antibodies to one toxin could potentially cross-react and bind to the 
other toxin, and eventually functionally neutralize it to an attenuated extent. However, we 
found that the DMAbs were highly specific, and there was no cross-specific binding in serum 
from animals that received a single plasmid (either DMAb A or DMAb B).  
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Figure 3-4: Serum IgG from immunized animals binds to Clostridium difficile toxoid A:  Mice 
were immunized once with DMAb plasmids. Serum from immunized animals was tested for 
binding to C. difficile toxoids A in an ELISA.  Ninety-six well plates were coated with 0.5 μg/ml 
of C. difficile toxoids A, and blocked with 5% BSA for 2 hours at RT. Serum was added at a 
dilution of 1:50 in duplicate. Plates were incubated for 2 hours at RT. Bound antibody was 
measured using HRP-conjugated secondary antibodies and developed using TMB. 
Absorbance was measured at 450 nm. The mean+95% CI of 4 mice/group were graphed. 
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Figure 3-5: Serum IgG from immunized animals binds to purified Clostridium difficile toxoid 
B:  Mice were immunized once with DMAb plasmids. Serum from immunized animals was 
tested for binding to C. difficile toxoid B in an ELISA.  Ninety-six well plates were coated with 
0.5 μg/ml of C. difficile toxoid B, and blocked with 5% BSA for 2 hours at RT. Serum was 
added at a dilution of 1:50 in duplicate. Plates were incubated for 2 hours at RT. Bound 
antibody was measured using HRP-conjugated secondary antibodies and developed using 
TMB. Absorbance was measured at 450 nm. The mean+SEM of 4 mice/group were graphed. 
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  3.4.5 IgG elicited by a single intramuscular immunization is transported to the 
intestine 
 
CDAD is almost always isolated to the gut(47). Septicemia from CDI is very rare, and not a 
disease state that is relevant to targeting by a vaccine. However, all vaccines being tested 
against CDAD are delivered peripherally(33, 56, 94, 95, 106). The inherent challenge that all these 
platforms share is the need for antibodies elicited by vaccination to traffic to the intestinal 
mucosa, where they can exert their effects. A sufficient quantity of antibody needs to traffic 
to the intestine to ensure neutralization of toxins released upon infection or recurrence. 
Clinically, low titers of antitoxin IgG in mucosal extracts have been correlated to severity of 
disease symptoms(70, 79, 143).  Here, we looked for IgG antibodies elicited by immunization 
with DMAb plasmids in fecal pellets and cecal contents. Fecal pellets from 4 mice per group 
were pooled at days 7 and 14 post immunization. Cecal contents were obtained after 
euthanasia at day 21. These samples were homogenized and resuspended in fecal extract 
buffer (composition described in methods) and centrifuged for 20 minutes at a high speed. 
Supernatants from this process were used to detect mucosal antibody levels by ELISA (Figure 
3-5). Our data suggests that there is a degree of transudation of the DMAb antibodies to the 
gut, and the quantity of antibody in both fecal pellets and cecal contents was similar.   
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Figure 3-6 DMAbs are detectable in mucosal extracts :  IgG levels in mucosal extracts were 
quantified via capture ELISA. Levels were quantified from pooled fecal pellets at day 7 and 
day 14, and intestinal contents post euthanasia at day 21. Fecal pellets and cecal contents 
were resuspended in fecal extract buffer. They were then homogenized for 15 minutes over 
ice, and centrifuged for 20 minutes at 13,200 RPM. The supernatants were harvested and 
analyzed in an ELISA. Plates were coated with 10 μg/ml of human IgG Fc fragment and 
blocked for 2 hours with 5% BSA. Mucosal extracts were added in duplicate and incubated at 
RT for 2 hours. Bound antibody was quantified using HRP-conjugated secondary antibodies, 
and the plate was developed with TMB. Absorbance was read at 450 nm. Means +95% CI 
were graphed in C).   
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3.5 Discussion 
 
Clinically, passive immunotherapy is an appealing treatment option for the 
immediate relief of symptomatic CDAD(117, 139). It provides a non-antibiotic means of 
alleviating the damage caused by tcdA and tcdB while preserving the intestinal microbiome. 
Monoclonal antibody therapy may have a key role to play in the treatment and management 
of recurrent CDAD. While offering a specific, targeted solution, the broad clinical application 
of monoclonal antibodies is precluded by the cost and relative inefficiency of production(121–
123). The immune response to an injection of monoclonal antibodies is another limiting 
factor, with most antibodies being strongly antigenic, and capable of raising a sustained 
auto-antibody response.  
Here, we utilized the DNA vaccine platform to formulate fully human monoclonal 
antibodies against the receptor binding domains of the toxins of C. difficile. In vivo 
electroporation was used as the method of delivery, to ensure efficient uptake of DNA by 
cells surrounding the site of injection. The singularly important advantage that this approach 
imparts is a miniscule cost of production, in comparison to recombinant monoclonal 
antibodies. In addition, advances in molecular biology and synthetic biology permit the 
usage of a variety of antigens as the targets to DNA encoded monoclonal antibodies, 
theoretically permitting an antigenically versatile immunotherapy. 
Monoclonal antibody therapy is currently being tested in multiple clinical trials as a 
suitable method for alleviating recurrent CDAD(117, 119, 139). Antibodies against the two toxins 
of C. difficile were originally raised in humanized mice upon immunization with whole or 
fragmented C. difficile toxins, and selected based on their capacity to protect the animals 
from systemic disease(117). The safety and immunogenicity of these antibodies was evaluated 
in Phase I clinical trials(139). They were found to have no effect on acute disease or symptoms, 
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but reduced the rate of recurrence by almost 20%, with a single infusion(119). Phase II clinical 
trials have been performed as well, with evidence suggesting that the administration of the 
monoclonal antibody to toxin B alone is sufficient to control recurrence(80, 119). While early 
reports suggest that this might end the long running debate regarding the need for 
immunity to either toxin, and not both, it is advisable to continue evaluating the role of toxin 
A in disease.  
In this study, we report the design, construction and expression of two monoclonal 
antibodies that target the receptor binding domain of the toxins of C. difficile. These 
plasmids were synthesized from publicly available sequences of Bezlotoxumab and 
Actoxumab, monoclonal antibodies currently in clinical trials(119, 139). In vitro transfection 
revealed that the plasmids were efficiently transcribed, translated and correctly assembled 
before being secreted out of cells. Antibodies in transfected tissue culture supernatants 
were also able to bind to purified antigens in an ELISA. The kinetics of expression and 
antigen specific binding were next tested in immunodeficient mice, which offered a good 
model to examine the expression of the DMAb plasmids without the interference of 
background antibody responses. A single immunization was found to generate a microgram 
level serum antibody titer that peaked at day 14 and persisted at the same level till day 21, 
at which point animals were sacrificed. Importantly, we could detect the antibodies in both 
fecal pellets and intestinal contents, proving that they successfully traffic to the mucosal 
surfaces, their primary site of action in a hypothetical challenge. This was the crucial hurdle 
to overcome in the potential application of this technology to a challenge model of infection 
and disease. Antibodies were then tested for their ability to bind to purified antigens from 
the bacterium, to validate the design and specificity of their VH and VL regions.  We found 
specific binding of both antibodies to their cognate toxin antigen, but detected negligible 
cross-reactivity. This is most likely an artifact of their synthetic specificity, as opposed to 
antibodies generated as a response to a vaccine antigen. Our next step in the development 
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of these DMAbs is to test their ability to neutralize C. difficile toxins in vitro. This is turn 
would inform their testing in a challenge model, to evaluate their protective efficacy from a 
lethal challenge with C. difficile spores.  
Thus, in conclusion, we present data showing 1) the expression and efficient 
assembly of DNA encoded monoclonal antibodies to the receptor binding domain of C. 
difficile toxins A and B, 2) antigen specific binding of these antibodies in vitro, 3) the 
persistent expression of functional antibody for 21 days post single immunization in 
immunodeficient mice, 4) the detection of antibody in mucosal preparations of feces or 
intestinal contents, and 5) the capacity of these antibodies in serum to bind their cognate 
antigen.   
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C. difficile infection is a continually escalating public health issue in the developed world. In 
recent years, its epidemiology has altered, with a greater number of community-onset 
infections showing that CDI is no longer contained within healthcare environments(43). 
Several risk factors have also been associated with heightened susceptibility to both CDI and 
symptomatic disease. Statistically, the number of hospitalizations due to CDI or CDAD has 
steadily increased(39), and shows no sign of abating. Within the hospital environment, 
gastrointestinal surgery and antibiotic usage remain the most potent risk factors(39). When 
coupled with advanced age and immune suppression (whether a consequence of cancer or 
transplant surgery), these risk factors sharply increase the likelihood of developing recurrent 
disease(46, 144). While none of these risk factors individually renders patients unresponsive to 
treatment, the usage of large doses of antibiotics in a hospital environment has been 
documented to cause several long-term health problems, not the least of which is drug 
resistance in commonly found bacterial pathogens. Modern treatment regimens have 
adopted a gradual escalation of both doses and number of drugs being used to treat 
recurrent CDAD(52). The recent introduction of Fidaxomicin, a poorly absorbed macrocyclic 
antibiotic that specifically targets C. difficile with minimal ablation of the gut microbiome has 
resulted in a greater number of successfully cleared infections, but even this powerful and 
specific treatment has been unable to reduce the overall burden of recurrent infections(145). 
Taken together, this information sharply highlights the need for an efficacious and 
protective vaccine to CDAD in both immunocompetent and immunocompromised 
populations, as well as an immediately acting immunotherapy, whose application would be 
part of the initial diagnosis upon admission to a hospital.  
A vaccine that elicits successful seroconversion in the immunosenescent population 
is urgently needed, and may be the biggest challenge facing the field of vaccinology as it 
pertains to C. difficile currently. As the population at greatest risk of developing recurrent 
disease in an aging society, it is pragmatic to consider developing vaccines specific to the 
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immunosenescent. All the vaccines currently in clinical trials to treat C. difficile, targeting 
either colonization or disease, have been tested in trials tailored for the aging, with all 
participants above the ae of 65 (see Table 1). While promising in immunocompetent adults, 
these approaches have failed to elicit similar responses and results in the immunosenescent. 
Vaccines developed by Pfizer (genetically modified full-length toxin A and B), Sanofi-Pasteur 
(highly purified toxin A and B) and Valneva (recombinant fusion of the receptor binding 
domains of both toxins) have notably failed to generate seroconversion in a large cohort 
from at-risk populations(140), which merits further study into the causes of failure of the 
vaccine response, as well as the development of technologies and methods of delivery that 
specifically boost the immune responses in the aging.  
A relatively underutilized platform in the field of vaccines for the immunosenescent and 
immunocompromised, the DNA vaccine platform may offer a workable solution to the 
problem of seroconversion. Here, we offer evidence that the immune response elicited by 
two immunizations with a DNA vaccine encoding the receptor binding domains of C. difficile 
toxins A and B, administered along with in vivo electroporation, resulted in the protection of 
aged, immunosenescent mice that have been documented to have a weaker antibody 
response, from a lethal challenge with C. difficile spores of a strain homologous to the 
vaccine antigens. This protection is notable, given the truncated immunization schedule and 
the absence of any adjuvants, which suggests that the vaccine is protective on its own. It 
also offers evidence of a vaccine showing complete protection in an immunosenescent 
model. However, much testing remains to be done at the preclinical stage. This study shows 
immunogenicity in aging animals, but suffers from low statistical power. The experiments 
performed here need to be repeated to attain statistical significance and ensure that these 
results are reproducible. In addition to this, protection from multiple strains of C. difficile, 
especially in the light of the emergence of multiple hypervirulent, drug resistant strains that 
cause greater morbidity and mortality, typically through the production of greater-than-
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average amounts of toxin.  The mechanism of immune induction by this vaccine is yet to be 
characterized, in the context of immunocompetent and immunosenescent animals. These 
knowledge gaps are significant when examined in the context of the immunosenescent 
model developed in our laboratory. We have performed primary infection studies in young 
and aged mice and characterized the immune response to infection with multiple strains. 
Pertinent findings include a drastic reduction in numbers of naïve and mature B-cells. TFH 
cells, which are vital cogs in the germinal center reaction. Weaker germinal center reactions 
result in ineffective class switching and somatic hypermutation of antibodies. These defects 
cumulatively cause a systemic reduction in antibody titers, and the prevalence of low affinity 
antibodies in the circulation. Mucosal IgA is also affected, and less effective in aged mice 
(Unpublished data, Bernui and Kutzler).  
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Figure 4-1: The role of a C. difficile toxin vaccine in the aged: Toxin specific immune 
responses are required for effective protection from CDAD. In the aged, the threshold of 
protection is altered by the presence of risk factors that predispose individuals to recurrent 
disease. Theoretically, these individuals would require a higher serum immune response to 
toxins to impart protection from disease. In the figure, the dashed blue line indicates the 
immune response raised by aged individuals. On its own, this response is insufficient to 
impart protection from CDAD, even after resolution of infection. The response indicated by 
vaccination (bold blue line in the figure) raises the immune response above the infection 
threshold, and protects individuals from symptomatic CDAD.   
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There is also a need to ensure protection from multiple strains of C. difficileIt is 
foreseeable that protection from the most potent strains of C. difficile, like the BI/NAP1/027 
strain(146), will require the usage of adjuvants to boost the immune response, as well as 
higher doses, or a greater number of them. The DNA vaccine platform is well positioned in 
this respect, with multiple adjuvants showing promising results in boosting responses to 
DNA immunization. The advantage that DNA based adjuvants offer is the possibility of a 
synergistic usage of multiple molecular adjuvants, to strongly boost both peripheral and 
tissue specific immune responses, like those of the intestinal mucosa.  
  Gut-Associated Lymphoid Tissue (GALT) is an important immunoanatomic site, with 
a strong concentration of B, T and Dendritic cells, all of which are needed in concert to 
produce a sustained, protective immune response. The converse of this is that the GALT is 
deeply deficient in these cell populations in senescence, creating a challenge in the 
generation of a vaccine response. A potential solution to this quandary is the usage of 
adjuvants specific to the mucosa, the ideal outcome being an augmented recruitment of 
immune cells, that can then internalize and present vaccine antigens, boosting the immune 
response to them. In the DNA vaccine milieu, earlier studies from our laboratory and 
collaborators have demonstrated the potential for chemokine adjuvants(109, 113, 147). Mucosae-
associated chemokine (MEC) or CCL28 has been shown to boost the mucosal immune 
response to vaccine antigens by increasing recruitment of antigen presenting cells to the 
mucosal epithelium(147). However, MEC remains to be tested in concert with the C. difficile 
vaccine, and this is an avenue for further investigation. We hypothesize that the co-delivery 
of the vaccine with MEC will boost the antibody titers generated by the vaccine and enhance 
the protective effect, from both homologous and heterologous strains of C. difficile in an 
aging murine model.  
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Immunosenescence lengthens the time needed to raise a sufficiently strong 
adaptive immune response. When coupled with the attenuated innate immune response in 
senescent populations, this creates a significant period during which there is little to no 
immune activity that can protect from infections. In the context of C. difficile infections, this 
is a key period during which recurrent infections may develop or flare up. Passive 
immunotherapy, via preformed monoclonal antibodies is a good option for these situations. 
If administered in sufficient quantities, antibodies to the toxins of C.difficile can bind to, and 
neutralize toxins secreted by the initial infection before they bind to epithelial cell receptors 
and are internalized. In theory, this initial immune clearance can protect patients from 
disease symptoms until a lasting, strong adaptive immune response is raised, and the 
infection is cleared. The usage of passive immunotherapy has been documented and tested 
in multiple clinical trials, the results of which demonstrated a successful reduction in 
recurrent disease(119, 139). However, the antibodies had no effect on symptoms and acute 
disease, and have been shown to exert their functions by directly binding to and neutralizing 
toxins.  
Passive immunotherapy is not without its flaws, however. The primary limitation is 
the limited half-life of monoclonal antibodies. The eventual degradation of monoclonal 
antibodies will necessitate repeated doses and boosters to maintain a protective titer. In 
addition to this, monoclonal antibodies have poor oral bioavailability, meaning that the only 
route for delivery is intravenous infusion. A significant hurdle is the development of an 
immune response to monoclonal antibodies. From the point of view of a basic immune 
response, monoclonal antibodies are proteins, which are strongly antigenic. The usage of 
fully human monoclonal antibodies does not preclude the development of an immune 
response against them. When coupled to their short half-life, this immune response sharply 
reduces the window during which the infusion of antibodies offers protection. In the context 
of CDAD, passive immunotherapy can offer a means of protecting colonized individuals from 
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recurrence events, if applied upon entry into the hospital for elective procedures, for 
instance.  
Here, we proposed the usage of a new DNA-based platform that allowed for the 
production of fully human monoclonal antibodies specific to the receptor binding domain of 
C.difficile toxins A and B as an immunotherapeutic. We have demonstrated stable expression 
of our DNA plasmids post immunization in an animal model, and antigen specific binding of 
the antibodies generated by this immunization. However, we take cognizance of the most 
important piece of data we are missing. The functionality of the antibody, and the capacity 
to neutralize toxins is yet to be extensively tested. We performed an initial experiment in 
which serum from animals immunized with DMAbs A and B failed to neutralize toxins A and 
B  ex vivo (Data not shown).   We have successfully begun to demonstrate the application of 
the platform to a pertinent clinical question. Our next steps in the development and analysis 
of these DNA-encoded monoclonal antibodies, subsequent to determining their capacity to 
neutralize toxins, is their testing in immunocompetent mice, to examine the generation of 
antibodies against the DMAbs, as well as their testing in an infection model, to evaluate its 
protective efficacy in the context of a lethal infection.  
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Figure 4-2: The role of an immune therapy in protection from CDAD:  Immune therapies 
that involve a circulating serum antitoxin antibody are an emerging option in the treatment 
of CDAD. We propose to induce a high titer of circulating, neutralizing antibody by 
immunizing at-risk individuals pre-emptively, such that a titer of antibody above the 
infection threshold is constantly maintained. In the figure, the dashed blue line indicates the 
immune response to the toxins, which is insufficient to protect from symptomatic disease on 
its own. The bold blue line indicates the antibody response elicited by immunization with 
monoclonal antibodies, which maintains a titer above the infection threshold.   
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In addition to this, we believe that there is scientific merit to the idea of a 
combination approach, which would involve the usage of both the DMAb and the DNA 
vaccine to combat initial and recurrent disease. We propose the immunization with the 
DMAb and DNA vaccine, followed immediately by a spore challenge whose peak coincides 
with the peak expression of DMAbs. Depending on the successful survival of this infection, 
we propose boosting with the DNA vaccine before rechallenging mice, to model recurrent 
infections. Challenges we expect to encounter in the design of this experiment include the 
potential for interference between the DMAbs and the antibodies elicited by the vaccine, 
which may be solved by staggering the immunizations, such that there is enough time 
between each to preclude immune interference. We would also like to examine the 
mechanisms by which both of our vaccines protect, and if the protection imparted is strain 
specific.   In conclusion, here we have presented data to back the potential for DNA vaccines 
as a platform for successful immunity in the immunosenescent, and as a mode of providing 
early passive immunotherapy at a reduced cost, with a heightened safety profile.  
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